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On 11 September 2006, Noel Ahern TD, Minister 
of State with responsibility for drugs strategy, 
launched the report of findings from the Research 
Outcomes Study in Ireland (ROSIE).1 A team at 
the National University of Ireland, Maynooth, 
completed the study on behalf of the National 
Advisory Committee on Drugs (NACD). This report 
focuses on outcomes for adult opiate users at one 
year following entry to treatment. Minister Ahern 
welcomed ‘this timely research which provides 
much needed information on how well people 
do when they go for drug treatment’. Dr Des 
Corrigan, chairperson of the NACD, reiterated 
the report’s main conclusion – ‘that investment in 
opiate treatment services leads to benefits to the 
individual drug user, to their family and to the rest 
of the community and that this investment must 
be continued’.
At baseline, the study recruited 404 opiate 
users aged 18 years or over entering treatment 
at inpatient facilities (hospitals, residential 
programmes and prisons) or outpatient settings 
(community-based clinics, health board clinics and 
general practitioners). The opiate users selected 
were entering treatment for the first time, or were 
returning to treatment after a period of absence, at 
any one of 54 services nationwide. The interview 
schedule collected data on: 
•  drug use in the 90 days preceding the interview, specifically, type, frequency, quantity and cost;
•  measures of harmful practices and consequences;
•  health status, using a self-rated physical and psychosocial health assessment;
•  social functioning, including accommodation, employment, and involvement in crime;
•  mortality, using information obtained from the participants’ contacts and the General  
Mortality Register. 
The participants were interviewed at intake (baseline), at six months following entry to treatment 
(not presented) and again at one year after intake. The baseline data were collected between 
September 2003 and July 2004. Of the 404 opiate users interviewed at intake, 373 (92%) were 
traced one year later, of whom 305 were interviewed. Of the other 68 who were traced, 66 did 
not wish to participate in the follow-up interview and two had died.  The characteristics of the 
99 individuals who were not interviewed one year after intake did not differ from those of the 
interviewees. The data presented in this article compares the experience at intake to that at one 
year for the 305 participants interviewed at both time-points. 
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Dr Catherine Comiskey, Principal 
Investigator, presenting the first findings 
from ROSIE. (Photo: Lar Boland)
There was a reduction in the proportion of 
participants who reported using heroin in the 
90 days preceding data collection, from 81% 
at intake to 48% at one year. The average 
frequency of heroin use by participants in a 
90-day period reduced from 43 out of 90 days 
at intake to 16 out of 90 days at one year. 
The average quantity of heroin consumed 
each day over a 90-day period decreased from 
0.9 grams at intake to 0.3 grams at one year. 
There was a corresponding reduction in the 
average amount spent on heroin on a typical 
day, from €75 at intake to €24 at follow-up. 
There were large reductions in the proportions 
of participants who reported use of non-
prescribed methadone, cocaine powder, crack 
cocaine and non-prescribed benzodiazepines 
at one year compared to the baseline 
interview. There were smaller reductions in 
cannabis and alcohol use over the same time 
period.  
The proportion of participants reporting use of 
more than one drug decreased from 78% at 
intake to 50% one year later.
The proportion of participants who reported 
injecting drug use in the 90 days preceding 
data collection decreased from 46% at intake 
to 29% at one year. The reported average 
number of days injecting over a 90-day period 
decreased from 21 out of 90 days at intake 
to 9 out of 90 days at one year. There was a 
corresponding decrease in the average number 
of times participants injected per day, from 
1.8 at intake to 0.8 at one year. There was a 
small decrease in the proportion reporting an 
overdose, from 7% at intake to 4% at follow-
up.
Between intake and one-year follow-up, there 
were reductions in the numbers of participants 
reporting 5 of 10 common symptoms of 
physical illness experienced by drug users; 
there were reductions also in the numbers 
of men reporting 6 of 12 selected symptoms 
of mental illness experienced by drug users. 
Women participants did not report reductions 
in the selected symptoms of mental illness. 
The average number of visits by participants 
to a general practice, or to employment, 
educational or homeless services, had 
increased at the time of follow-up.  
The proportion of participants reporting 
involvement in acquisitive crime decreased 
from 31% at intake to 14% at one year. In 
addition, the proportion reporting selling or 
supplying drugs reduced from 31% at intake 
to 11% at one year.
Of the 305 participants interviewed at both 
time points, 7% were not using drugs at 
the time of entry to treatment, while 27% 
were not using drugs one year later. Of the 
285 participants for whom treatment status 
was reported, 30% completed their index 
treatment, 14% were transferred to another 
treatment site, 18% did not complete their 
index treatment and 38% were still in their 
index treatment. At the one-year follow-up 
interview, 82% of these 285 participants were 
either continuing in their index treatment or 
had commenced another treatment episode.  
Adult opiate users reported positive changes 
in drug use, risk behaviour, health status, 
service contact and criminal behaviour at 
one year following entry to treatment, which 
indicates that treatment for these opiate users 
was beneficial. According to the authors, drug 
treatment contributed to changes in the lives 
of opiate users, but it is not feasible to isolate 
the exact contribution of the treatment, on its 
own, from that of other influences. (Jean Long)
1.  Cox G, Comiskey C, Kelly P, Cronly J 
(2006) ROSIE Findings 1: Summary of 1-
year outcomes. Dublin: National Advisory 
Committee on Drugs. 
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The annual report of An Garda Síochána for 2005 
was published earlier this year.1The report is the main 
source of information on crime in Ireland and includes 
information on crimes recorded by An Garda Síochána 
in which criminal proceedings were taken. 
The report includes a chapter on drug offences, giving 
the number of such offences in which proceedings 
were taken, by Garda division and by drug type; the 
number, volume and types of drug seized by the 
gardaí and customs officers; and the number, age 
and gender of persons charged, as well as the nature 
of the offence. The Garda annual report is primarily 
a reflection of the activities and effectiveness of law 
enforcement agencies, rather than of the prevalence 
of drugs or the incidence of drug-related crime.  
However, the Garda reports are a useful indicator of 
trends in drug offending over time.2
Figure 1 shows trends in the number of drug supply 
(s.15 Misuse of Drugs Act MDA 1977), possession 
(s.3 MDA 1977) and total drug offence prosecutions 
between 1995 and 2005. The majority of prosecutions 
are for drug possession, which increased from 5,065 
in 2004 to 7,432 in 2005, an increase of almost 50% 
(46.7%). 
 
Figure 2 compares trends in possession offences with 
the number of cannabis-related offences prosecuted 
from 1995 to 2005. It can be seen that most of the 
prosecutions which take place for drug possession are 
cannabis-related.  
 
 
 
 
 
 
Figure 3 compares cocaine-related prosecutions with 
those for heroin. The growing concern with the 
increase in the scale of the cocaine market in recent 
years in Ireland is reflected in the fact that, for the first 
time, cocaine-related prosecutions have eclipsed those 
for heroin. 
 
The Garda annual report also includes Information on 
drug seizures carried out by the Garda Síochána and 
the Customs Service.3 Drug seizure figures provide 
information about drug availability and supply and 
the impact of law enforcement efforts. Although the 
number of drug seizures in any given period can be 
affected by such factors as law enforcement resources, 
strategies and priorities, and by the vulnerability of 
traffickers to law enforcement activities, drug seizures 
are considered as indirect indicators of the supply and 
availability of drugs.4 Cannabis seizures account for the 
vast majority of all drugs seized. In 2005, of the 6046 
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Cocaine-related prosecutions 
eclipse those for heroin 
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Figure 1  Trends in possession (s.3 MDA), supply 
(s.15 MDA) and total drug offence prosecutions, 
1995–2005 
Source: Annual reports of An Garda Síochána 
1995–2005
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Figure 2  Trends in cannabis-related prosecutions 
and prosecutions for simple possession (s.3 
MDA), 1995–2005 
Source: Annual reports of An Garda Síochána 
1995–2005
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Figure 3  Drug offence prosecutions by drug 
type, 1995–2005 
Source: Annual reports of An Garda Siochána 
1995–2005
reported drug seizures, 3417 (56.5%) were cannabis-
related. Figure 4 shows trends in seizures of a number 
of selected drugs, excluding cannabis, between 
1995 and 2005. We can see a steady rise in cocaine 
seizures over the last two decades, with heroin seizures 
remaining stable and ecstasy seizures continuing to 
decline since 2000.
Figure 5 and Figure 6 look at trends in heroin-related 
prosecutions by Garda region. 
 
 
Figure 5 shows the trends in heroin-related prosecutions 
in the Dublin Metropolitan Region as a percentage of all 
such prosecutions. It can be seen that the vast majority 
of heroin-related prosecutions occur in Dublin. However, 
as shown in Figure 6, since 2000 there has been a 
steady increase in heroin-related prosecutions in the 
Eastern Region (Carlow/Kildare, Laois/Offaly, Longford/
Westmeath, Louth/Meath), from 24 prosecutions in 
2000 to 128 in 2005, and to a lesser extent in the 
South Eastern region (Tipperary, Waterford/Kilkenny, 
Wexford/Wicklow). It is clear that although heroin 
remains predominantly a Dublin-based phenomenon it 
is no longer confined exclusively to the capital. Further 
research would be required to determine whether this 
represents a shift or displacement in the heroin market 
outside the capital city. (Johnny Connolly)
 
1.  The Annual Report of An Garda Síochána for 2005 is 
available on the Garda website at www.garda.ie
2.  For a discussion about the data issues which arise in 
relation to the annual Garda reports see Connolly J 
(2006) Drugs and crime in Ireland. Overview 3.  
Dublin: Health Research Board.
3.  A detailed breakdown of this information is 
provided by the Customs Service on the Revenue 
Commissioners’ website at http://www.revenue.ie/
services/customs/cndt2000.htm  
4.  For a fuller discussion of these issues see Connolly J 
(2005) The illicit drug market in Ireland. Overview 2. 
Dublin: Health Research Board.
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Cocaine eclipses heroine (continued)
0
20
40
60
80
100
120
140
160
‘95
4
24
3
5
2
‘95
26
45
16
6
9
‘95
8
44
7
36
20
‘95
3
75
14
20
7
‘95
7
68
22
135
8
‘95
8
128
49
53
6
0
20
40
60
80
100
120
140
160
South Eastern Region
Eastern Region
Northern Region
Southern Region
Western Region
N
um
be
r 
of
 p
ro
se
cu
ti
on
s
Figure 6   Trends in heroin-related prosecutions 
by Garda region outside the Dublin Metropolitan 
Region, 2000–2005
Source: Annual reports of An Garda Síochána 
2000–2005
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Figure 4   Trends in the number of seizures of 
selected drugs, excluding cannabis, 1995–2005
Source: Annual reports of An Garda Síochána  
1995–2005
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Figure 5   Trends in total heroin-related 
prosecutions and those in the Dublin 
Metropolitan Region, 1995–2005
Source: Annual reports of An Garda Síochána 
1995–2005  
The Medical Bureau of Road Safety (MBRS) recently 
published its annual report for 2004.1 The Bureau 
is an independent forensic body responsible under 
the Road Traffic Acts for the chemical testing 
of intoxicants in driving in Ireland. The Bureau 
analyses specimens of blood and urine from 
people suspected by the gardaí of driving offences 
to determine their alcohol content. The Bureau 
also supplies the equipment used by the gardaí 
for indicating the presence and concentration of 
alcohol in breath specimens taken in Garda stations 
(Evidential Breath Testing). The legal limit for 
alcohol varies depending on the type of specimen 
taken (Table 1).
Table 1­   Legal limit for alcohol in blood, 
urine and breath
Specimen Legal limit for alcohol
Blood 0–80mg per 100ml of blood
Urine 0–107mg per 100ml of urine
Breath 0–35μg per 100ml of breath*
*  μg = microgram. A microgram is one millionth 
of a gram, a milligram (mg) is one thousandth 
of a gram.
The Bureau issues certificates indicating the 
alcohol level in the blood and urine specimens it 
receives and in the breath specimens taken by the 
equipment it supplies. In a small number of cases, 
certificates cannot be issued because of some 
defect in the specimen or in the documentation 
accompanying it. Table 2 shows the number 
of certified blood, urine and breath specimens 
over the five-year period 2000 to 2004 and the 
proportion over the legal limit for alcohol.
The drop in the number of blood and urine 
specimens certified over the period 2000 to 
2004 is due to a decrease in the number of 
specimens received, which in turn is due to the 
implementation and extension of the Evidential 
Breath Testing programme since 2000. The 
proportion of certified specimens over the legal 
limit for alcohol, while high, shows a gradual 
decline over the five years. The reason for this 
decrease is unclear; it may be due to an increasing 
number of specimens from drivers whose 
impairment could be due to the presence of a drug 
or drugs other than alcohol.
On 21 July 2006 a number of key initiatives set 
out in the Road Traffic Act 2006 came into effect. 
One of these gives the gardaí the power to carry 
out random breath testing (mandatory alcohol 
testing). A recent nationwide survey of adults (18 
years or over) by Alcohol Action Ireland found 
that a majority (87%) of respondents favoured the 
introduction of random breath testing to detect 
drink-drivers.2
The MBRS also analyses blood and urine specimens 
for the presence of seven different drugs or drug 
classes, namely: amphetamines, metamphetamines, 
benzodiazepines, cannabinoids, cocaine, opiates 
and methadone. For the five-year period 2000 to 
2004, specimens testing positive for one or more 
drugs were forwarded to the State Laboratory or 
the UK Laboratory of the Government Chemist for 
confirmatory analysis. Prior to 2002, the Bureau 
tested specimens for the presence of drugs only at 
the request of the gardaí. However, since 2002 all 
specimens that are under the legal limit for alcohol 
are routinely tested for the presence of drugs. The 
numbers of specimens tested, screened positive 
and confirmed positive over the period 2000 to 
2004 are shown in Table 3.
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Driving while over the legal limit for 
alcohol or under the influence of drugs
Since 2002 all 
specimens that 
are under the 
legal limit for 
alcohol are 
routinely tested 
for the presence 
of drugs.
Table 2    Number of certified blood, urine and breath specimens and the proportion over 
the legal limit for alcohol, 2000 to 200
Certified specimen  2000  2001  2002  2003  2004
Blood  3,952  3,004  2,218  2,187  2,348
% over the legal limit  93.2%  92.3%  91.2%  90.4%  89.1%
Urine  2,559  1,831  1,457  1,475  1,671
% over the legal limit  91.2%  87.9%  88.6%  87.9%  82.5%
Breath  3,075*  6,527  7,770  6,525  6,951
% over the legal limit  82.2%  81.8%  81.4%  80.8%  80.1%
Total  9,586 11,362  11,445  10,187  10,970
% over the legal limit  89.1%  85.6%  84.2%  83.9%  82.4%
Source: Medical Bureau of Road Safety annual reports 2000 to 2004.
*  The Evidential Breath Testing programme commenced in late 1999; the low figure in 2000 represents a 
gradual introduction of testing equipment during this year.
     
 
As was expected, the proportion of tested 
specimens confirmed positive for drugs dropped 
dramatically in 2002 following the introduction of 
routine testing of all specimens under the legal limit 
for alcohol. In 2002, 24 specimens were tested for 
drugs at the request of the gardaí; 15 were tested 
on request in 2003 and 25 in 2004. The figures in 
Table 3 reveal that in recent years just over 40% of 
specimens that were under the legal limit for alcohol 
contained one or more drugs. 
A study on driving under the influence of drugs 
in Ireland carried out by the MBRS in 2000 and 
2001 found a strong trend of increased drug 
positivity with decreased level of alcohol.3 Among 
the specimens that had minimal or zero levels 
of alcohol, 68% tested positive for one or more 
drugs. Of all specimens that were under the legal 
limit for alcohol, 33.1% tested positive for one or 
more drugs, compared to 14.2% for specimens 
over the legal limit. The fact that drug prevalence 
was more than twice as high in those specimens 
under the limit for alcohol suggests that incapacity 
because of drug taking may have been a reason 
why these drivers were stopped in the first place. 
Of the specimens testing positive for the presence 
of drugs but under the legal limit for alcohol, 
45.6% tested positive for only one drug, while 
54.4% tested positive for two or more drugs. 
This high level of polydrug use was not observed 
in specimens that were over the legal limit for 
alcohol, of which only 17.6% tested positive for 
two or more drugs, not including alcohol.
The study concluded that driving under the 
influence of drugs was a significant problem in 
Ireland. The recent figures from the Bureau’s 
Annual Report 2004 suggest that this problem is 
increasing. (Hamish Sinclair)
1.  Medical Bureau of Road Safety (2006)  
Report for the year ended 31st December 2004. 
Dublin: Medical Bureau of Road Safety.
2.  Alcohol Action Ireland (2006) Alcohol in Ireland: 
time for action. A survey of Irish attitudes.  
Dublin: Alcohol Action Ireland.
3.  Cusack DA, Leavy CP, Daly L and Fitzpatrick P 
(2004) Driving under the influence of drugs in 
Ireland: results of a nationwide survey 2000–2001. 
Dublin: Medical Bureau of Road Safety.
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Driving under the influence (continued)
Table    Number of blood and urine specimens tested for the presence of drugs, 
screened positive and confirmed positive, 2000 to 200
Specimen 2000 2001 2002 2003 2004
Total tested 78 131 388 416 569
  of which screened positive 71 115 233 266 354
      of which confirmed positive 56  96 117 179 247
% of tested specimens confirmed positive 71.8% 73.3% 30.2% 43.0% 43.4%
Source: Medical Bureau of Road Safety annual reports 2000 to 2004.
     
 
Dr Vincent P Dole, whose research in the 1960s 
established that methadone could be used to treat 
heroin addiction, died on 1 August 2006, aged 93. 
In 1964, Dole and his research partner Dr Marie 
Nyswander experimented with treating people 
addicted to heroin with a synthetic drug known as 
methadone. At the time, methadone was known 
predominantly as a painkiller and, although it was 
recognised as having addictive properties, it was 
believed to have limited adverse effects on the 
human body. 
In early trails during 1964 with 22 people addicted to 
heroin, Dole and Nyswander noted that methadone 
satisfied the physical cravings of addiction but did 
not make users high or subject them to violent 
mood swings. When treated with methadone and a 
comprehensive programme of rehabilitation, patients 
returned to education, obtained jobs and became 
reconciled with their families. Indeed, Dole and 
Nyswander emphasised that treating the medical 
needs of people addicted to heroin with methadone 
needed to be complemented by giving equal 
attention to their social-reintegration needs: ‘The 
most important services needed during this [initial] 
phase of treatment were help in obtaining jobs, 
housing and education.’1 
Their studies showed that people with heroin 
addiction could be maintained on prescribed doses  
of methadone; they remained physically dependent 
on the drug but were able to conduct otherwise 
normal lives. These findings sparked the creation of 
hundreds of methadone programmes worldwide.  
The studies also contributed to a shift from a 
primarily moral approach to the treatment of heroin 
users to one that treated them as medical patients. 
For this groundbreaking piece of work, society 
will remain indebted to the pioneering vision and 
scientific outlook of the late Dr Dole.  (Martin Keane)
1.  Dole VP and Nyswander M (1965) A medical 
treatment for diacetylmorphine heroin addiction:  
A clinical trial with methadone hydrochloride. 
Journal of the American Medical Association, 193(8).
Dr Vincent Dole: An obituary
Among the 
specimens that 
had minimal 
or zero levels 
of alcohol, 68% 
tested positive 
for one or more 
drugs.
Published in June 2006, Towards 2016: Ten-Year 
Framework Social Partnership Agreement 2006–20151 
adopts a new lifecycle framework to address key 
social challenges that individuals in Irish society at 
different stages of life will face over the next 10 
years. This means a focus on the needs of children, 
young adults, people of working age, older people 
and people with disabilities. The lifecycle framework 
will place these stages at the centre of policy 
development and delivery, assessing the risks facing 
individuals at these various stages and the supports 
available to them to address those risks. An agreed 
vision and key long-term goals for each stage of the 
lifecycle are identified in the framework Agreement, 
together with a programme of agreed priority 
actions in pursuit of each of the long-term goals. 
The issues of illicit drugs and alcohol are addressed 
in relation to children (0–17 years) and young adults 
(18–29 years). 
•  The Agreement contains a commitment, identified 
as a priority action in relation to children, to 
monitor prevalence trends in smoking and 
substance use through the National Health and 
Lifestyle Surveys and the European School Survey 
Project on Alcohol and other Drugs (ESPAD) 
(Towards 2016: Section 30.2). 
•  A cross-departmental team chaired by the Office 
of the Minister for Children is developing an 
initiative to test models of best practice which 
promote integrated, locally-led, strategic planning 
for children’s services. The initiative will focus on 
children who are at risk of suffering from multiple 
disadvantage relating to poverty and social 
exclusion, and on vulnerable families exposed to, 
among other things, risks from substance abuse 
(Towards 2016: Section 30.3). 
•  Young adults are recognised as having three 
particular health needs – combating substance 
misuse, reducing alcohol-related harm and the 
prevention of suicide. While not identifying any 
priority actions or innovative measures in relation 
to substance misuse or alcohol, the Agreement 
notes the establishment of a fifth, rehabilitation, 
pillar in the National Drugs Strategy, the potential 
for better co-ordination between the areas of 
drugs and alcohol, and the allocation of additional 
funding in 2006 to develop drug-related facilities 
and services for young people. It notes that the 
recommendations of the Working Group on 
Alcohol, established under Sustaining Progress, will 
be implemented. (Towards 2016: Section 31.3)
Under the heading of Road Safety, Towards 2016 
endorses the passing of the Road Traffic Bill 2006, 
which provides the necessary statutory backing for a 
range of specific measures set out in the Road Safety 
Strategy 2004–2006. The Agreement prioritises 
the need to introduce mandatory roadside alcohol 
testing. It makes no reference to drug driving or to 
mandatory drug testing. Subsequent to the release of 
the Agreement, on 19 July 2006 the Road Traffic Act 
2006 came into effect. Under the Act, the gardaí have 
the power to carry out mandatory roadside alcohol 
testing. Drivers who are breathalysed and found to be 
over the legal limit2 will face between three months 
and four years off the road. Those who refuse to give 
a breath test face two years off the road.  
The new ten-year framework Agreement outlines the 
governance framework and monitoring mechanisms 
that will support implementation of the Agreement. 
The Steering Group established under Sustaining 
Progress 2003–2006 will be reconvened and will 
assume overall responsibility for managing the 
implementation of this Agreement. As heretofore, 
there will be ongoing quarterly meetings to review, 
monitor and report on progress, and an annual 
formal meeting of all parties to the Agreement. In 
addition, the Agreement provides for a streamlined 
outcomes-focused approach to monitoring and 
reporting of progress on social inclusion matters 
under the lifecycle framework. A formal review will be 
conducted during 2008. Furthermore, government 
has committed to involving the Social Partners in 
the development of policy, to ensuring meaningful 
input by the Partners into the shaping of appropriate 
responses to individual policy issues and the design of 
implementation arrangements, and to providing the 
Social Partners, with sufficient notice, information and 
appropriate processes for engagement. (Brigid Pike)
1. Retrieved 26 July 2006 at www.taoiseach.gov.ie  
2.  See H Sinclair ‘Driving while over the legal limit 
for alcohol or under the influence of drugs’ on 
p.5 of this issue for a definition of the legal limit 
for alcohol on the breath.
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New social partnership agreement 
addresses drugs and alcohol 
The Agreement 
prioritises the 
need to introduce 
mandatory 
roadside alcohol 
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In July of this year (2006), an Oireachtas 
committee published a report which considered 
the question of whether or not alcohol should be 
included in a national substance misuse strategy.1 
Having examined the issues, the committee was 
‘unequivocally of the view that alcohol should be 
included in the drugs strategy.’
The committee made this recommendation 
following a review of the prevalence and range 
of alcohol-related problems currently experienced 
in Ireland; consideration of the political and 
administrative impediments to the implementation 
of an integrated, national alcohol policy to date; 
and having examined the possibility of extending 
the mandate of the National Drugs Strategy to 
include alcohol. 
As the report explains, it is now widely 
acknowledged that alcohol-related problems 
extend beyond a single disease category 
(alcoholism) and include a range of social and 
health issues which may be either chronic and 
ongoing or acute and once-off in nature. It is also 
necessary to consider the effects of alcohol-related 
problems on others (family members, friends, 
neighbours or work colleagues) and the financial 
burden on society as a whole when attempting to 
formulate a suitable policy response.  
The two reports from the Strategic Task Force 
on Alcohol, 2002 and 2004, have compiled very 
clear evidence to document the wide range of 
negative effects which alcohol consumption has 
on Irish society.  Over the past forty years, research 
carried out in the biomedical and social sciences 
has confirmed that the kinds of alcohol-related 
problems experienced in this country are a direct 
reflection of our national drinking habits and that 
the only effective solution is to use social measures 
aimed at changing these drinking habits.  
The committee reported a disparity between the 
preventative strategies for which there was popular 
support and those for which there was evidence 
of effectiveness.  The most popular strategies 
were education (of the general public and of 
school-going children); the provision of alternative 
(alcohol-free) recreational activities for young 
people; and the expansion of treatment systems 
for those with alcohol dependence.  Evaluation 
research indicates that these approaches have little 
or no positive effect.  
The strategies which are demonstrably effective in 
improving public health and public order include 
fiscal measures to increase the price of alcoholic 
beverages, restrictions on the numbers of retail 
outlets and days and hours of sale, tougher drink 
driving countermeasures, and bans or restrictions 
on alcohol advertising and promotion. There 
are two main reasons why these strategies are 
perceived to be politically difficult. Firstly, they 
are threatening to the drinks industry, an industry 
which contributes to the economic well-being of 
the country and has well-established links to Irish 
political life; and secondly, they may prove to be 
electorally unpopular since they are aimed at the 
drinking population in general (rather than at 
specific subgroups within this population).  
It is interesting to note that criticism of this report 
from the Drinks Industry Group of Ireland (DIGI) 
focused on the amount of alcohol being consumed 
per person and per adult (defined as 15 years and 
older) in Ireland between 2001 and 2005. Since 
2001 the amount of alcohol being consumed has 
fallen among these groups by 5.9% and 6.8% 
respectively. The committee reported European 
figures from the 1990s and DIGI attributes the 
peak in consumption levels during this period 
to the large proportion of the population aged 
between 18 and 25 years. The DIGI acknowledged 
that there are serious issues with the misuse of 
alcohol among sections of the population and that 
the industry was committed to addressing these 
problem areas.  However, it stated ‘we do not 
believe it is necessary, fair or wise to demonise the 
majority of people who enjoy a drink responsibly, 
simply because of problems caused by a minority’.
In response, the chairperson of the committee, 
Cecilia Keaveney, stressed that it was not the 
intention of the report to demonise drink.  She said 
that ‘in some cases alcohol had beneficial effects, 
but rather than picking holes in data, the various 
interests should be working together to resolve 
the problem.’  Indeed, the committee noted that 
public support for alcohol control measures is 
growing, as evidenced in the recent attitudinal 
survey published by Alcohol Action Ireland (2006).
Researchers have long recognised that alcohol is an 
issue which cuts across many different sectors of 
government and that the different sectors do not 
necessarily operate from an agreed policy agenda.  
For over thirty years the WHO has recommended 
that national governments should create 
management structures which facilitate the drafting 
and implementation of integrated, national alcohol 
policies based upon research findings. 
While the evidence-based strategies have been 
known in Ireland for more than twenty years and 
have been recommended in policy documents 
on several occasions, this has not led to ongoing 
implementation. No permanent management 
structures have been established to give effect to 
such recommendations. 
The report shows how problems relating to illicit 
drugs, which have a much shorter history, are 
being managed through the National Drugs 
Strategy. Reform of the Irish public sector under 
The inclusion of alcohol in a national 
substance misuse strategy
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the Strategic Management Initiative (SMI) in 
the late 1990s, which aimed to improve the 
management of cross-cutting issues and create 
‘joined-up government,’ provided the model for 
the National Drugs Strategy. The structures set 
in place combine ‘top-down’ co-ordination with 
‘bottom-up’ or community-level participation in 
the policy process.
These structures have facilitated the emergence of 
a policy process over the past ten years in which 
policy objectives are clearly stated; actions necessary 
for the realisation of objectives are identified; the 
agencies which have specific responsibility for 
working towards the attainment of the various 
objectives are identified; and key performance 
indicators and timeframes are established. A detailed 
policy framework, Building on Experience: National 
Drugs Strategy 2001–2008, was published in 2001 
following a national consultation process. A mid-
term review of this strategy was published in 2005.  
While the mid-term review offered evidence of 
mixed outcomes regarding the implementation 
of the strategy, it provided evidence that the 
structures have succeeded in keeping all the major 
stakeholders (statutory and non-statutory) involved 
in an on-going process of working towards agreed 
objectives. The committee argues that the National 
Drugs Strategy has brought consistency and 
coherence to the complex arena of Irish drug policy.
It is significant that during the public consultation 
process before Building on Experience was drafted, 
members of the public, particularly those outside 
Dublin, identified alcohol as their major source of 
concern. The committee argues that this concern 
with alcohol issues and the accompanying sense of 
frustration that alcohol is not part of the National 
Drugs Strategy continue to be reflected in the work 
of the regional drugs task forces. It concludes that 
the five-pillar model of the National Drugs Strategy 
(supply reduction, prevention, treatment, research, 
and rehabilitation) appears to offer an ideal 
framework for a comprehensive policy approach to 
alcohol issues. (Sarah Fanagan)
1.   Houses of the Oireachtas Joint Committee on 
Arts, Sport, Tourism, Community, Rural and 
Gaeltacht Affairs (2006) Ninth Report: The 
inclusion of alcohol in a national substance misuse 
strategy. Dublin: Stationery Office.
A national substance misuse strategy (continued)
Guidelines setting out the functions, composition 
and operation of joint policing committees 
(JPCs), established under the Garda Síochána Act 
2005, were published in June.1 The guidelines 
were prepared by the Minister for Justice in 
consultation with the Minister for the Environment 
and, following a recommendation by the Joint 
Oireachtas Committee on Justice, Equality, Defence 
and Women’s Rights, with Mr Noel Ahern, Minister 
of State with responsibility for drugs strategy.2
JPCs, which are to be established in each of 
the 114 local authority administrative areas 
throughout the State, will bring together 
representatives from the local authority, gardaí, 
public representatives and representatives of the 
community and voluntary sector to discuss and 
make recommendations on matters affecting the 
policing of the area. The guidelines propose the 
establishment of pilot JPCs in the following areas: 
Fingal, Offaly and Wicklow County Councils; 
Dublin, Galway, Limerick and Waterford City 
Councils; Drogheda and Sligo Borough Councils; 
Athy, Arklow, Ballinasloe, Birr, Bray, Edenderry, 
Greystones, Leterkenny, Mallow, Tralee, Tuam, 
Tullamore and Wicklow Town Councils. In Dublin 
city, five sub-committees corresponding to the 
operational areas of the City Council will also be 
established. 
From January 2007 an evaluation of the pilot phase 
will begin. After mid 2007, JPCs will be established 
in all local authorities until the next local elections 
in 2009. The guidelines also make provision to 
ensure that Garda representation on the JPCs is 
of appropriate rank and seniority, and highlight 
the importance of ensuring gender equality on 
the JPCs. The primary functions of the JPCs are to 
serve as a forum for consultation, discussion and 
recommendations on local policing matters and 
to keep under review levels of crime, disorder and 
anti-social behaviour, including the patterns and 
levels of misuse of alcohol and drugs. 
The guidelines also cover such issues as the 
chairing of JPCs, the circumstances in which 
they can meet in public and in private and the 
procedures by which members of the public can 
raise issues of local concern. Section 36(2)(d) of 
the Act provides for the establishment of local 
policing fora by a JPC. Supplementary guidelines 
for local policing fora are to be drawn up at a 
later date. However, in light of Action 11 of the 
National Drugs Strategy, the guidelines stipulate 
that ‘priority will be given to establishing local 
policing fora in all Local Drugs Task Force areas and 
other areas experiencing problems of drug misuse’ 
(p.16). (Johnny Connolly)
1.  Department of Justice, Equality and Law Reform 
(2006) Garda Síochána Act 2005: Joint Policing 
Committee Guidelines. Dublin: Department of 
Justice, Equality and Law Reform.
2. Drugnet Ireland, Issue 15, Autumn 2005.
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The European Prevention Prize, an accolade 
given by the Council of Europe, was presented to 
Kilkenny’s 421 Peer Drugs Education Programme 
at a recent awards ceremony in Vilnius, Lithuania. 
The Pompidou Group awards this prize every 
two years in order to highlight good-quality drug 
prevention projects that have successfully involved 
young people in their design and implementation. 
The Kilkenny initiative, along with a project from 
Norway, was chosen from 31 entries by a panel 
that comprised six young people from the Russian 
Federation, Norway, the Netherlands, Romania, 
the UK and Turkey and experts in the field from 
the Pompidou Group. The two winners received a 
trophy, a diploma and prize money of €2,000. 
The story of the emergence of the 421 Programme 
goes back to the year 2003 when a school 
chaplain in Kilkenny identified the need for an 
innovative approach to providing drug education 
in local schools. It was felt that the traditional 
adult-delivered drug education approach had its 
limitations, and that it could be strengthened 
by more active participation of young people 
themselves in both design and delivery. In 
response, two drug education workers from the 
HSE and the local youth service developed what is 
now the 421 Peer Education Programme. 
The overall aim of the 421 initiative is to provide 
meaningful education to young people on drugs 
and the main risks associated with their use. The 
main objective is to introduce peer education by 
training groups of students to design and deliver 
drug education in their schools. The 421 initiative 
trains fourth-year students to design and deliver 
drugs education to first-year students. The older 
students are trained over a three-day period by 
local youth workers and community drug workers 
from Ossory Youth, and the drugs education officer 
from the Carlow/Kilkenny HSE substance misuse 
team. 
The training includes modules on the following: 
attitudes to substance misuse, drug facts, signs and 
symptoms, patterns of drug use, peer education 
skills, planning a programme and presentation 
skills. Schools pay a fee of €20 for the training of 
each student. These students then design their 
own six-session drugs education programme, 
which they deliver to the all first-year classes in 
their school. This is usually done in the context 
of Social, Personal and Health Education (SPHE) 
classes. 
The 421 Programme has been in existence since 
2004. To date (summer 2006) the programme has 
trained 92 fourth-year students from four schools 
in Co Kilkenny. These young people have gone on 
to provide drugs education to approximately 880 
first-year students. The initiative relies extensively 
on internal evaluations to make changes and 
respond to issues arising. The whole programme 
is due to undergo an external evaluation soon. 
Funds for the evaluation have been secured and 
an external evaluator is in discussion with the 
programme team.  
An article in issue 18 of Drugnet Ireland, ‘Inequality 
and the stereotyping of young people’, highlighted 
two recent pieces of research among young people 
in Ireland. Devlin1 reported that young people 
perceived and experienced levels of inequality and 
disrespect from certain adult groups in society 
including the gardaí and school teachers, and 
Lalor and Baird2 highlighted the crucial role that 
peers play in the everyday lives of young people, 
particularly as providers of ‘new information’. 
The article in issue 18 suggests that perhaps it 
would be wise for adult groups that deliver drug 
education to young people to reflect on their 
methods of engagement and give serious thought 
to training young people themselves in the design 
and delivery of peer education. The 421 initiative 
is an excellent example of how this approach can 
be developed. It will be interesting to assess the 
effectiveness of this intervention and to see how it 
is received by its target audience; these questions 
will receive some attention in the forthcoming 
external evaluation. Finally, a special word of 
thanks to Mr Mel Bay from Ossory Youth for 
providing information on the history and operation 
of the 421 initiative. (Martin Keane)
1.  Devlin M (2006) Inequality and the stereotyping 
of young people. Dublin: The Equality Authority. 
2.  Lalor K and Baird K (2006) Our views – Anybody 
listening? Researching the views and needs of 
young people in Co Kildare. Kildare: Kildare Youth 
Services.
Peer drugs education programme in 
Kilkenny wins major European award
At the prize-giving ceremony in Vilnius, 
from left: Mel Bay, Kilkenny City Drugs 
Initiative; Marion Hearne, Loreto 
Secondary School, Kilkenny; Susan 
Barnes, HSE Substance Misuse Team 
Carlow/Kilkenny; Rachel Walsh, 421 Peer 
Educator, Loreto Secondary School.
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In July 2006 the European Foundation of Drug 
Helplines (FESAT) published the results from its 
eleventh monitoring project.1 Since the beginning of 
2001 FESAT has been collecting information every six 
months on the types of person contacting helplines 
throughout Europe, the content of these calls and how 
this has changed compared to the previous six months. 
The main objective of this monitoring is to identify the 
emergence of new drugs and new drug trends as early 
as possible.
During the second half of 2005 six helplines received 
calls about drugs that had not been reported to them 
before. Helplines in Cyprus and Italy reported calls 
about Ketamine, an anaesthetic that has hallucinogenic 
effects. The Cypriot helpline also reported questions 
about LSA, a naturally occurring psychedelic found 
in some plants. In Austria, calls were received about 
mCPP, a piperazine-derived designer drug commonly 
sold as ecstasy. One Belgian helpline reported receiving 
15 calls about Efedrine (Ephedrine), a stimulant that 
suppresses appetite. In Finland, calls were received 
about GBL, which when ingested turns into GHB, 
producing effects such as relaxation, mild euphoria 
and drowsiness. Lastly, in Norway, two new drugs were 
reported by one helpline: Vallergan, an antihistamine 
with sedative effects reportedly used by drug users to 
relieve sleeping problems, and DMT, a hallucinogenic 
drug similar to LSD.
The FESAT report also notes a continuation of the 
increasing trend in the number of calls about cocaine 
and about alcohol; whether these were used in 
combination is not stated.
Unpublished data from the Drugs/HIV Helpline in 
Ireland show that the number of calls about the 
combined use of alcohol and cocaine as a proportion 
of all calls concerning alcohol or cocaine increased 
threefold over the period 2002 to 2006 (Table 1). 
However, trends based on helpline calls should always 
be interpreted with care. Aileen Dooley, Drugs/HIV 
Helpline manager, stresses that helpline staff record 
only what is revealed during calls, and a caller might 
not always mention a second drug (Aileen Dooley, 
personal communication). In addition, helpline staff are 
increasingly aware of the need to record mention of 
alcohol. So the observed increase may be due, in part, 
to better recording practices.
In July 2005, the Health Promotion Unit of the 
Department of Health and Children launched the third 
phase of the National Drugs Awareness Campaign, 
which was aimed at raising awareness of the dangers 
of mixing cocaine with other drugs, especially 
alcohol.2 When cocaine and alcohol are taken together 
they combine in the body to form another drug, 
Cocaethylene, which is more toxic than either drug 
alone. Cocaethylene can seriously affect the normal 
functioning of the heart. This recent phase of the drug 
awareness campaign specifically targeted recreational 
settings, such as pubs and clubs. Anecdotal reports 
suggest that cocaine is increasingly available in Irish 
pubs, which tends to link the drug with alcohol, 
giving it an ‘acceptability’ that needs to be addressed.3 
(Hamish Sinclair)
1.  Hibell B (2006) FESAT Monitoring Project – Changes 
during the second half of 2005. FESAT (The European 
Foundation of Drug Helplines). www.fesat.org
2.  Keane M (2005) National Drugs Awareness 
Campaign. Drugnet Ireland, Issue 15: 7.
3.  Sinclair H, Long J (2006) Health Service Executive 
facilitates workshop on cocaine. Drugnet Ireland, 
Issue 18: 11.
More information about FESAT can be found on the 
website of the European Foundation of Drug Helplines 
at www.fesat.org
The Drugs/HIV Helpline in Ireland is a 
confidential, freephone, active listening service 
offering non-directive support, information, 
guidance and referral to anyone with a question 
related to substance use or HIV and sexual 
health. Set up in July 1997, the service is funded 
and managed by the Health Service Executive 
South Western Area on behalf of the HSE South 
Western, East Coast and Northern Areas. The 
freephone number is 1800 459 459. The Helpline 
manager is Aileen Dooley. 
Identifying new drugs and new drug 
trends with the help of drug helplines
Table 1­   Number of calls to the Drugs/HIV Helpline about the combined use of alcohol and 
cocaine as a proportion of all calls concerning alcohol or cocaine in the first five months of 
the year, 2002–2006.
Number of calls in the first five months of the year
  2002  2003  2004  2005  2006
All calls about either cocaine or alcohol  178  246  309  277  403
Calls about the combined use of cocaine and 
alcohol
 8  17  41  30  60
Proportion of calls about the combined use of 
cocaine and alcohol
 4.5%  6.9%  13.3%  10.8%  14.9%
Source: Aileen Dooley, Drugs/HIV Helpline
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The Southern Regional Drugs Task Force (SRDTF) 
was established in 2003 by the National Drugs 
Strategy Team. 
The SRDTF recently published its Strategic Plan1 to 
address drug and alcohol misuse in Cork and Kerry. 
The Plan is the result of extensive research and 
consultation with a range of individuals and 
organisations to determine the nature and extent of 
the problem of drug and alcohol misuse in Cork  
and Kerry.
The background research carried out in the 
preparation of this Plan included a detailed profile 
of the SRDTF. Current drug- and alcohol-related 
services, the uptake of services and gaps in service 
provision were highlighted. A study by Dr Tim 
Jackson, Smoking Alcohol and Drug Use in Cork and 
Kerry (2004), the repeat of a 1999 study, was used 
for comparative purposes.  
The research and consultation process revealed that:
•   Drug and alcohol use had increased across all 
types of drugs in the region between 1996 and 
2004. 
•   Cannabis use had significantly increased and was 
the most popular illicit drug of choice.
•   The increase in illicit drug use was most 
pronounced in the 15–19 and 20–24-year age 
groups.  
•   Societal tolerance of high alcohol and illicit drug 
use had significantly increased.  
•   Addiction was a feature for many prisoners and ex-
prisoners, as well as for their immediate families.  
•   There was a specific illicit drug trade aimed 
directly at non-nationals.
•   The number of people accessing treatment for 
both drug and alcohol misuse had increased by 
300% since 1999.  
•   The key/link worker approach was identified as 
offering flexibility in treatment and rehabilitation, 
but no such resource exists in the region.
Some of the key recommendations of the Strategic 
Plan are:
•   The development of partnership between state 
and voluntary sectors in the provision of treatment 
for drug and alcohol misuse.
•   The development of the role of key/link worker 
which will ensure continuity between each phase 
of treatment. These workers can play a significant 
role in ensuring that the pathway to rehabilitation 
is made accessible to all clients. 
•   That the needs of families affected by drug and 
alcohol misuse must be addressed in order that 
rehabilitation can take place within the family unit.
•   The level of treatment service provision should 
reflect the level of drug and alcohol misuse.
•   Recognition of the roles of alternative treatment 
methods rather than relying solely on drug-based 
treatments.
The Strategic Plan was submitted to the National 
Drugs Strategy Team for consideration and funding 
has been approved for the implementation of a 
detailed Action Plan over the three-year period 
2005–2008. (Siobhán Reynolds)
1.  Southern Regional Drugs Task Force (2005) 
Strategic Plan 2005–2008. Cork: SRDTF.
Southern Regional Drugs Task Force: 
Strategic Plan 2005–2008
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The Health Service Executive (HSE) South Eastern 
Area published its annual report entitled Data 
co-ordination overview of drug misuse 20051 in 
June 2006.  The report comprises three sections: 
treatment services, education and prevention, and 
supply and control. 
The section on treatment services analyses data 
collected from statutory and voluntary drug and 
alcohol treatment agencies, acute general hospitals 
and psychiatric hospitals in the HSE South Eastern 
Area based in HSE South. The data from the drug 
and alcohol treatment services are returned to the 
National Drug Treatment Reporting System. 
The total number of contacts with treatment 
services in 2005 was 2,786.  This is an increase 
of 237 clients compared to the 2004 figure.  As 
the report notes, this may be a true increase or 
may be the result of improved reporting from the 
participating services.  Contacts with treatment 
services include those by clients continuing in 
treatment from the previous year, clients who were 
assessed but not treated, clients who were treated, 
and concerned persons.  Some 142 concerned 
persons, the majority (76%) of them female, 
contacted treatment services in the south-east in 
2005. 
Substance misuse in the HSE South 
Eastern Area
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The Dublin North East Drugs Task Force recently 
published a review of FÁS Special Community 
Employment (CE) programmes in the area.1 
FÁS Special CE was designated the main vehicle 
through which vocational and employment skills 
training would be delivered in local drugs task 
force (LDTF) areas.2 The review by Lawless1 reflects 
the views of staff and participants engaged in 
CE and includes a number of key learning points 
that merit attention from policy makers, service 
providers and other relevant stakeholders engaged 
in responding to the needs of drug users. 
How is FÁS CE perceived: Rehabilitative or 
vocational?
The primary aim of FÁS Special CE projects in 
LDTFs is to provide vocational and employment 
skills training to improve the chances of clients 
finding employment. Yet, Lawless reported that the 
majority of respondents in the Dublin North East 
area continued to view CE as the main mechanism 
for delivering drug rehabilitation, with therapeutic 
functions as the primary role. Education and 
training were viewed as the least important role. 
An overall review by Bruce3 of FÁS CE in LDTF areas 
reported a similar finding, with project staff and 
participants expressing the view that CE was being 
used to provide personal development and relapse-
prevention skills, with little attempt to provide 
vocational training options. 
Critique of health services as part of inter-
agency approach
Lawless reported that all respondents cited the lack 
of inter-agency work as one of the main barriers 
to the full effectiveness of CE. The majority of 
respondents expressed the view that the Health 
Service Executive (HSE), which they felt should 
be responsible for drug rehabilitation work, had 
abdicated its responsibility and transferred this 
work to FÁS, which was not equipped for the task. 
Many felt that, without the strategic involvement 
of the HSE, local community groups were out of 
their depth in trying to do the work they were 
involved in. The review by Bruce identifies a similar 
experience among project staff, who expressed 
their frustration at the lack of HSE involvement in 
their work with clients. 
The role of methadone, dosage reduction and 
detoxification
Lawless reported that staff and participants had 
strong views on the role of methadone in the 
overall context of FÁS CE. Methadone was viewed 
as a key part of the initial stages of stabilisation; 
however, it was felt that, more often than not, it 
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The combined total of new referrals who were 
treated and clients who returned to treatment after 
an absence was 1,944. Of these:  
•   75 per cent were male and 25 per cent female;
•   7.5 per cent were under the age of 18 years, 
and 43 per cent were aged between 20 and 34 
years;
•   Alcohol (66%) was the most common main 
problem substance for which treatment was 
sought, followed by cannabis (16.5%) and 
heroin (8%);  
•   The number of clients whose main problem 
substance was cocaine increased considerably, 
from 25 cases in 2004 to 85 cases in 2005;
•   Of the clients who had used a drug, 41 per cent 
reported that cannabis was the first drug they 
had ever used;
•   39 per cent of clients reported using a secondary 
substance, the main ones being cannabis (16%), 
alcohol (7%) and ecstasy (6%);  
•   63 per cent of clients treated for alcohol and 
69 per cent treated for a drug as their main 
problem substance were treated for the first 
time. 
Of all clients treated in the south-east in 2005 
(including clients continuing in treatment from the 
previous year), 152 (6%) had injected a substance. 
Of those who had injected, 66 (43%) had shared 
injecting equipment at least once. (Sarah Fanagan)
1.  Kidd M (2005) Data co-ordination overview of 
drug misuse 2005. Waterford: HSE South Eastern 
Area. 
Substance misuse in the HSE South Eastern Area (continued)
The role of vocational training in Dublin 
North East Drugs Task Force projects
had become the sole and final solution. The criticism 
was not of methadone treatment but of the lack 
of options available to clients. This ‘one size fits all’ 
approach was heavily criticised and, indeed, runs 
counter to the central premise of the National Drugs 
Strategy 2001–2008, which holds that drug misuse 
is the result of a complex interplay of factors and 
will not be alleviated by any one approach, but 
requires an array of options. Some respondents 
to the research survey by Lawless viewed the 
methadone programme ‘as a form of social control’ 
and ‘an abdication of the state’s responsibility’ 
(p.68) to provide a properly funded and structured 
treatment programme of options and pathways to 
rehabilitation. 
Additionally, clients reported that when they tried 
to take some responsibility for their own treatment, 
they very often got an adverse response from 
medical staff. Across the four special CE projects in 
the Dublin North East Task Force area, clients spoke 
of themselves or others being treated with disrespect 
by the medical staff, of not being involved in their 
own treatment plans and of feeling frustrated in their 
attempts to reduce their dosage or to detox from 
prescribed medication.
The option of threatened sanctions as favoured 
by clients as a demand reduction tool
Lawless reported that clients favoured the option of 
urine samples being taken for testing twice or three 
times a week, despite the sanctions that a failed 
test would entail. Clients expressed the view that 
they could ‘get round’ having one test per week 
and continue to dabble in drugs if they wished, 
but having to submit to two or three tests would 
prove more difficult and so reduce the likelihood of 
their using illicit drugs. Clients felt that this would 
strengthen their motivation to stay off drugs. 
Research by Ginexi et al.4 found that by far the 
greatest barrier to labour force participation and 
employment for persons in treatment for drug use 
over a three-year period was continued use of illicit 
drugs. 
The need for more intensive vocational input to 
enable client progression
Clients expressed the view that participation in the 
CE programme had enabled them to further their 
personal development, but were frustrated at how 
little progress they had made in terms of education 
and training and how few move-on options were 
open to them. Most of all, they wanted to leave the 
project with more formal qualifications. They wanted 
to see more work placement and work experience 
built into the programme and felt that structured 
move-on options were essential. Research by Lidz 
et al.5 reported that where a relaxed rather than an 
intensive approach is taken to vocation training, the 
results can be quite discouraging for clients. 
An alternative approach to CE, based on the 
findings of the evaluation
Taking the three components of dosage reduction, 
use of sanctions and intensive vocational inputs that 
have been requested by clients, service providers 
can use an approach that is showing promise in 
improving employment opportunities for clients 
on methadone. Research by Kidorf et al.6 suggests 
that reducing methadone dosage, the threat of 
sanctions and the application of intensive vocational 
training support can be effectively combined to 
help clients in methadone treatment progress to 
employment. The Motivated Stepped Care (MSC) 
approach requires all patients who complete one 
year of treatment to secure work, with continued 
methadone treatment contingent upon securing 
employment. The approach includes a highly 
intensive Job Seekers Skills Training group where 
specialists motivate clients to tackle the personal 
barriers between them and employment, with the 
objective of developing the self-efficacy of the client 
so that he or she can take responsibility for their job 
seeking behaviour. Based on preliminary evaluation 
of this approach, Magura et al.7 suggested that it 
is one of the few in the vocational training field 
to demonstrate promise when applied to people 
in methadone treatment. The adoption of this 
approach in LDTF areas is a feasible option and 
should at least be piloted to test its applicability in an 
Irish context. However, such an approach will require 
the development of inter-agency co-operation and 
much greater involvement of clients in the design 
and management of a structured care plan, with 
buy-in from all relevant stakeholders. As we approach 
the final stages of the current National Drugs 
Strategy, it is incumbent on both policy makers and 
service providers to invest in the progression needs 
of clients who have been maintained on methadone 
for some time. (Martin Keane)
1.  Lawless K (2006) Listening and learning: evaluation 
of Special Community Employment programmes 
in Dublin North East. Dublin: Dublin North East 
Drugs Task Force. 
2.  Ministerial Task Force on Measures to Reduce 
the Demand for Drugs (1996) First report of the 
ministerial task force on measures to reduce the 
demand for drugs. Dublin: Stationery Office
3.  Bruce A (2004) FÁS Community Employment 
schemes in local drug task forces: a review. 
(Unpublished). 
4.  Ginexi EM, Foss MA and Scott CK (2003) 
Transitions from treatment to work: employment 
patterns following publicly funded substance 
abuse treatment. Journal Of Drug Issues, 33(2): 
497–518. 
5.  Lidz V, Sorrentino DM, Robinson L and Bunce S 
(2004) Learning from disappointing outcomes: 
an evaluation of prevocational interventions for 
methadone maintained patients. Substance Use 
and Misuse, 39(13–14): 2287–2308.  
6.  Kidorf M, Neufeld K and Brooner RK (2004) 
Combining stepped care approaches with 
behavioural reinforcement to motivate 
employment in opiod-dependent outpatients. 
Substance Use and Misuse, 39(13–14): 2215–2238. 
7.  Magura S, Staines GL, Blankertz L and Madison 
EM (2004) The effectiveness of vocational services 
for substance users in treatment. Substance Use 
and Misuse, 39(13–14): 2165–2213.
The role of vocational training (continued)
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‘Working Together Works’
Dublin North East Task Force hosts Open Day
Noel Ahern TD, Minister of State with responsibility for drugs strategy, launched 
the open day hosted by Dublin North East Drugs Task Force at their offices in 
Donnycarney on 29 June.  ‘Working Together Works’ was both educational and fun, 
with guest speakers, information stands and entertainment throughout the day.  
Picture shows, from left: Tom O’Brien, Task Force Coordinator; Councillor Deirdre 
Heaney; Minister Ahern; and George Ryan, Task Force chairperson.  
Johnny Connolly of the DMRD speaking at  
‘Working Together Works’ in June.
New Life Choir was among the many bands,  
choirs and youth groups providing  
entertainment to the large attendance.
The Directory of Alcohol, Drugs and Related Services 
in the Republic of Ireland 2005 was published by the 
Health Promotion Unit, Department of Health and 
Children, in May 2006.
Health Promotion Unit contact details: Tel: 01 6354372; 
Email: healthpromotionunit@health.irlgov.ie
Website: www.healthpromotion.ie
In May 2006 some 25 members of Dáil Éireann 
(including eight Independents) debated a private 
member’s motion on Ireland’s drugs policy.1 Both 
the motion and the contributing speakers endorsed 
the National Drugs Strategy (NDS)2 and its strategic 
objective, ‘to significantly reduce the harm caused 
to individuals and society by the misuse of drugs 
through a concerted focus on supply reduction, 
prevention, treatment and research’ (NDS: Section 
6.7). The motion called for increased resources 
and an intensification of efforts to support the full 
implementation of the NDS (see Table 1). The 
opportunity was not taken, however, to debate 
the larger strategic question of whether or to what 
extent Ireland’s policy objectives in relation to illicit 
drugs were still appropriate. 
It might have been an opportune time to initiate 
such a debate because, starting in some 18 
months’ time, UN members, including Ireland, will 
be reporting on their actions in pursuit of the goals 
and targets set for the year 2008 in the UN Political 
Declaration on drugs3 and debating the next steps. 
In addition, the EU Drugs Action Plan 2005–20084 
and Ireland’s National Drugs Strategy 2001–20082 
will both be expiring. At UN level, the Commission 
on Narcotic Drugs, the UN’s central policy-making 
body dealing with drug-related matters, has 
already begun to prepare for the evaluation of the 
UN action plan.5 International, European and Irish 
non-governmental organisations (NGOs) have also 
begun to debate the alternatives to the approach 
favoured by the UN.6  
In Ireland, the Review Group that drew up 
the NDS in 2000/12 considered alternative 
strategic approaches, including broadening the 
harm-reduction approach to include heroin on 
prescription and/or injecting rooms (NDS: Section 
4.13.2). It also noted the debate regarding the 
decriminalisation of certain controlled substances 
(NDS: Section 5.2.5). The Review Group 
concluded, however, that these harm-reduction 
options were not appropriate but should be kept 
under review. 
Reporting in 2005, the Mid-Term Review (MTR) 
of the NDS7 reported that the current aims and 
objectives of the NDS were ‘fundamentally sound’ 
(MTR: Section 8.2). In relation to harm reduction, 
the MTR expressed the view that, ‘in light of the 
increase in the incidence of hepatitis C and the 
ongoing prevalence of HIV, higher priority should 
be given to the relevant actions in the Strategy 
[Actions 62 and 63 relating to needle exchange 
and other injecting paraphernalia]’ (MTR: Section 
5.23). The MTR did not, however, review the wider 
range of harm-reduction options considered by the 
Review Group in 2000/1. 
Given that the Steering Group that undertook the 
mid-term review did not present any evidence to 
support its conclusions regarding the fundamental 
soundness of the aims and objectives of the NDS, 
and given that there was a general consensus 
among contributors to the Dáil debate in May that 
both the supply of and demand for illicit drugs 
in Ireland had increased dramatically in the five 
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Politicians and the drugs debate 
Supply 
reduction
•   Target major drug traffickers
•   Ring-fence seized funds related to the drugs trade for development in communities 
worst affected by ‘drug scourge’
•   Appropriate sanctions, including sentences, for those involved in drugs trade
•   Increased resources for drug-related Garda activities
Prisons •   Ensure access for prisoners  to health and prevention policies and services, including 
harm-reduction strategies, equivalent to those available in the wider community 
Cocaine •   Formulate, resource and implement an action plan to address cocaine use
Treatment •   Increase funding to ensure waiting lists are eliminated
•   Encourage the HSE to return to ‘real partnership’ with community and voluntary 
groups in addressing problematic drug use
•   Expand spectrum of services
•   Ensure access to counselling and other medical services, without discrimination
Prevention •   Ensure take-up of widespread and well-resourced education programmes and 
campaigns
Grandparents •   Increase orphan-guardian allowance for grandparents looking after children of their 
drug-addicted offspring, in line with provision for foster parents
Socio-economic 
factors
•   Address poverty and inequality, including educational disadvantage
All-Ireland 
approach
•   Work on an all-Ireland basis to ensure application of strategic objectives in National 
Drugs Strategy
Strategic 
leadership
•   Appoint a Minister of State with sole responsibility for the drugs issue
Table 1­     Summary of measures included in Private Member’s Motion, Dáil Éireann,  
May 20061­
Starting in some 
18 months’ time, 
UN members, 
including Ireland, 
will be reporting 
on their actions 
in pursuit of 
the goals and 
targets set for 
the year 2008 in 
the UN Political 
Declaration on 
drugs.
years since the NDS was published, it might have 
been expected that the Dáil deputies would review 
the strategic aims and objectives of the NDS and 
consider whether the approach being followed was 
still both appropriate and sufficient. 
Arguably, the Minister of State with responsibility 
for drugs strategy, Noel Ahern TD, invited such 
debate when he stated, ‘The key drivers of the 
[illicit drugs] market include both economic factors 
and the attitude of societies towards illicit drug 
consumption.’8 While the minister elaborated on 
the economic factors, he did not explore the links 
between social attitudes and the drugs situation 
and the implications for drugs policy, and no other 
speaker took his cue.
Researchers in the area of Irish drugs policy suggest 
that there has long been a reluctance on the part 
of Irish politicians to address the wider strategic 
questions with regard to illicit drugs. It has been 
argued that, ideologically, there has been a cross-
party consensus that ‘drugs’ not only are a social 
problem in and of themselves but also exacerbate 
the crime problem in Ireland, and are evil and 
to be prohibited.9 It has also been argued that, 
sociologically, political leaders have generally not 
encouraged or participated in explicit public debate 
on the concept of harm reduction in relation to illicit 
drugs, in order to contain sensitive and potentially 
divisive national social issues.10 
A structural factor that may also inhibit politicians’ 
engagement with the strategic aspects of the 
drugs issue is the availability and accessibility of 
research-based evidence to support their analysis 
and deliberations. In reviewing the Research pillar 
of the NDS, the MTR reported that ‘substantial 
progress’ had been made in filling information gaps 
but urged agencies to make their information more 
readily available (MTR: Section 6.13). The MTR did 
not consider the associated question of whether 
and how information and research findings were 
translated into policy and practice. To what extent 
do researchers understand and work within the ‘real’ 
world of policy and practice, and to what extent do 
policy makers, including politicians, understand the 
value and methods of research and how to apply the 
lessons of research in formulating policy?11 
To enhance the translation process, a series of 
possible initiatives has been identified,12 including 
investment in long-term research strategies linked to 
national and EU policy concerns;  establishment of 
centres of excellence to co-ordinate and/or carry out 
research; the establishment of think tanks alongside 
the research centres, comprising academics, policy 
makers and practitioners, to offer detached reflection 
and cultural questioning on what the research means 
in a wider context, and alternative approaches 
and questions; and promotion of a stakeholder 
partnership comprising three-way collaboration 
between government, science and the market for 
the exchange of knowledge and the development of 
policy. (Brigid Pike) 
1.  Private Member’s Business. Drug Abuse: Motion 
(23–24 May 2006) Parliamentary Debates Dáil 
Éireann Official Report: Unrevised. Vol. 620, No 1, 
cols. 54–85 and Vol. 620, No 2, cols. 493–528.  
See www.oireachtas.ie 
2.   Department of Tourism, Sport and Recreation 
(2001) Building on experience: National drugs 
strategy 2001–2008. Dublin: Stationery Office. 
3.   UN Political Declaration. 9th plenary meeting of the 
UN General Assembly (UNGASS), 10 June 1998. 
A/RES/S-20/2. 
4.   EU Drugs Action Plan 2005–2008. 2005/C 168/01. 
5.   Commission on Narcotic Drugs (2006) Report on 
the forty-ninth session (8 December 2005 and 13-
17 March 2006).  E/2006/28, E/CN.7/2006/10. 
6.   At international level, see, for example, the websites 
of the Senlis Council at www.senliscouncil.org 
and the International Drug Policy Consortium 
at www.idpc.info  In Europe, on 6–7 November 
2006, ENCOD (European Coalition for Just and 
Effective Drug Policies) will be hosting a conference 
in collaboration with the GUE and Green Party 
factions of the European Parliament on ‘European 
Alternatives on Drug Policies – the Road to Vienna 
2008’; see www.encod.org for further information. 
In Ireland, on 28 August 2006, three NGOs – the 
Irish Penal Reform Trust (IPRT), Merchants Quay 
Ireland (MQI) and the Union for Improved Services, 
Communication and Education (UISCE) – held a 
public forum entitled ‘Rethinking the War on Drugs’; 
see www.iprt.ie for further information.
7.   Steering group for the mid-term review of the 
National Drugs Strategy (2005) Mid-term review 
of the national drugs strategy 2001–2008. Dublin: 
Department of Community, Rural and Gaeltacht 
Affairs.
8.   Ahern N (23 May 2006) Parliamentary Debates Dáil 
Éireann Official Report: Unrevised. Vol. 620, No 1, 
col. 69.
9.   Murphy T (2002) Drugs, crime and prohibitionist 
ideology. In O’Mahony P (ed.) Criminal Justice in 
Ireland. Dublin: Institute of Public Administration.
10.  Butler S and Mayock P (2005) “An Irish solution to 
an Irish problem”: Harm reduction and ambiguity 
in the drug policy of the Republic of Ireland. 
International Journal of Drug Policy, 16(6): 415–422.
11.  For a case study of how research has translated 
into policy and practice in Ireland, see McGarry K 
(2004) ‘An evidence-based policy in a moral panic: 
Linking local drugs task forces to drug treatment 
data’. MSc thesis, Trinity College, Dublin.
12.  See R Hartnoll (2004) Drugs and drug dependence: 
linking research, policy and practice – lessons 
learned, challenges ahead. Background paper 
for the Pompidou Group’s Strategic Conference 
on connecting research, policy and practice, 
Strasbourg, 6–7 April 2004. Strasbourg: Council of 
Europe Publishing Group, and Pompidou Group 
(2004) Connecting research, policy and practice: 
lessons learned, challenges ahead. Proceedings of 
Strategic Conference on connecting research, 
policy and practice, Strasbourg, 6–7 April 2004. 
Strasbourg: Council of Europe Publishing Group. 
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Politicians and the drugs debate (continued)
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To mark International Day against drug abuse and illicit 
trafficking (26 June), the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) published 
a thematic paper entitled ‘Hallucinogenic mushrooms: 
an emerging trend case study’.1 This paper is the first 
in a series of reports to be published under a new 
EMCDDA pilot project to explore the capacity in EU 
member states and the EMCDDA to detect, track and 
understand emerging drug trends in Europe. The 
project is called European Perspectives on Drugs, or E-
POD for short.
The detection and tracking of emerging drug trends 
demand a different approach to that of the traditional 
key epidemiological indicators2 used for monitoring 
the main types of drug use. While the key indicators 
developed by the EMCDDA since the mid-1990s 
provide reliable and comparable European drug data, 
they are not sensitive enough to detect emerging drug 
trends in a timely manner. The approach adopted by 
the EMCDDA in its E-POD pilot project was to collect 
and analyse information on hallucinogenic mushrooms 
in Europe from a range of sources (some non-
conventional) and within a limited timeframe (between 
July and October 2005). The work of detecting and 
monitoring emerging trends relies largely on locally 
based information sources that are close to the target 
drug-using groups. The sources used included:
•   Targeted surveys conducted in club or dance music 
settings
•   Telephone helplines, including the European 
Foundation of Drug Helplines (FESAT)
•   Information from retail outlets (e.g. ‘smartshops’, 
‘headshops’ and ‘grow shops’)
•   Information from national focal points
•   Published reports and scientific articles
•   Newspaper and magazine articles
•   Non-published (grey) literature
•   Internet websites and discussion groups
•   Personal communication with key informants.
The thematic paper highlights the growth in the 
marketing of hallugincogenic mushrooms by 
smartshops, internet shops and market stalls across 
Europe. This increase in availability has fuelled interest 
in such mushrooms and has led to an increase in their 
use. 
 
Surveys in 12 EU member states indicate that, among 
young people aged 15 to 24 years, lifetime use of 
hallucinogenic mushrooms ranges from less than 1% 
to 8%. In Ireland, the estimated lifetime prevalance of 
hallucinogenic mushroom use is 5.5%. However, the 
95% confidence interval around this estimate ranges 
from 4.2% to 6.9%, indicating that the prevalence 
could be as low as 4.2% or as high as 6.9%.3
The third European School Survey on Drugs and 
Alcohol (ESPAD) conducted in 2003 introduced a 
question about the use of hallucinogenic mushrooms.  
Across Europe, lifetime use of hallucinogenic 
mushrooms by schoolchildren (aged 15–16 years) 
ranged from 0% to 8%. In Ireland, the estimated 
lifetime prevalence was 4%.4 No confidence intervals 
were provided for this ESPAD estimate.
As might be expected, clubbing surveys in Europe 
show higher levels of hallucinogenic mushroom use 
among clubbers than among the general population of 
the same age. No clubbing surveys have been carried 
out in Ireland.
The thematic paper notes that, since 2001, six 
EU countries have tightened their legislation on 
hallucinogenic mushrooms, apparently in response 
to their increasing availability and use. In Ireland, 
legislation was introduced in January 2006 to ban the 
possession and sale of hallucinogenic mushrooms in 
their natural state.5 Heretofore, only possession and 
sale of such mushrooms in their dried or prepared state 
was unlawful. In the UK, tighter legislation introduced 
in July 2005 appears to have had an immediate impact 
on both the availability of hallucinogenic mushrooms 
and on the general volume of internet sales.
The EMCDDA points to a number of additional factors 
which may help limit the diffusion of this emerging 
trend. Unlike ecstasy, which is easy to take at a party or 
dance scene, mushrooms must be chewed or brewed 
in hot water. This cumbersome route of consumption 
is likely to serve as a barrier to widespread or frequent 
recreational use of mushrooms; it may also reduce the 
likelihood of young people witnessing others using 
mushrooms and possibly copying their behaviour. 
In addition, the unpredictable potency and negative 
effects, such as nausea and panic attacks, or the lack of 
sociable effects, may contribute to limiting recreational 
use of hallucinogenic mushrooms.
The E-POD pilot project contributes to the 
implementation of objective 41 of the EU Action Plan 
on Drugs (2005–2008) which calls for the development 
of ‘clear information on emerging trends and patterns 
of drug use and drug markets’. The EMCDDA 
thematic paper provides an important snapshot of 
the current status of hallucinogenic mushroom use, 
its consequences and the responses in Europe, using 
available data sources. In order to monitor trends, 
it will be necessary to repeat the data- collection 
and analysis exercise on a regular basis in the future. 
(Hamish Sinclair)
1.  Hillebrand J, Olszewski D and Sedefov R (2006) 
EMCDDA Thematic Papers – hallucinogenic 
mushrooms: an emerging trend case study. Lisbon: 
European Monitoring Centre for Drugs and Drug 
Addiction.
2.  The five key epidemiological indicators of drug 
use are (1) prevelance of drug use in the general 
population, (2) prevalence of problem drug use, 
(3) drug-related infectious diseases, (4) drug-related 
deaths, and (5) the demand for drug treatment. 
Objective 39 of the EU Action Plan on Drugs (2005–
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Emerging drug trends in Europe: a case 
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2008) calls for ‘reliable and comparable data on key 
epidemiological indicators’ and places responsibility 
on all member states to fully implement the five key 
epidemiological indicators.
3.  National Advisory Committee on Drugs and Drug 
and Alcohol Information and Research Unit (2006) 
Drug use in Ireland and Northern Ireland. 2002/2003 
drug prevalence survey: first results (revised) from 
the 2002/2003 drug prevalence survey – Bulletin 
1. Confidence Intervals. Dublin: National Advisory 
Committee on Drugs.
4.  Hibell B et al. (2004) The ESPAD Report 2003: Alcohol 
and other drug use among students in 35 European 
countries. Stockholm: The Swedish Council for 
Information on Alcohol and Other Drugs (CAN), 
Council of Europe, Co-operation Group to Combat 
Drug Abuse and Illicit Trafficking in Drugs (Pompidou 
Group).
5.  Connolly J (2006) Government bans sale of ‘magic’ 
mushrooms. Drugnet Ireland, Issue 17: 9.
Emerging trends: hallucinogenic mushrooms (continued)
The European Commission is currently seeking to 
establish a clear role for civil society in relation to drugs 
policy in the EU. It has defined what it means by ‘civil 
society’ and why it should be involved in drugs policy. 
How it should be involved is the question posed in the 
recent consultative document Green Paper on the role of 
civil society in drugs policy in the European Union.1
The Green Paper defines ‘civil society’ as ‘the 
associational life operating in the space between the 
state and market, including individual participation, 
and the activities of non-governmental, voluntary and 
community organisations’ (p. 5). Associational life 
includes non-governmental, voluntary and community 
organisations that represent service providers, the 
interests of professionals working in the drugs field, drug 
users or their families, and others who, while not working 
directly or primarily with drug policy, still have a valuable 
contribution to make, for example in relation to HIV/
AIDS. The Green Paper also explicitly includes ‘individual 
citizens who clearly make a significant commitment or 
contribution’ and ‘those affected by public policies, who 
might otherwise not be heard’ (p. 5). 
The three reasons given for involving civil society in drugs 
policy are consistent with the types of actors included 
in the definition of civil society – service providers and 
users: ‘to support policy formulation and implementation 
through practical advice, to ensure an effective two-way 
information flow, and to stimulate networking among 
civil society organisations’ (p. 5). 
The Green Paper outlines two possible mechanisms for 
engaging civil society in drugs policy:
•   a Civil Society Forum on Drugs, which would be a 
platform for regular structured dialogue between the 
European Commission and civil society, mainly on 
themes occurring in the EU Action Plan on Drugs; and
•   creating co-operation between civil society 
organisations  by linking networks under common 
themes as an informal, light and cost-effective way 
of structuring information flows and enabling a more 
effective consultation. 
 
Feedback is invited on the perceived benefits, added 
value or weaknesses of these two options, on whether 
the options are mutually exclusive, or could be 
combined, and on whether there are other possible 
mechanisms not mentioned in the Green Paper.
Whatever mechanism is finally chosen, it may be 
anticipated that it will not be the last word on how the 
European Commission engages with civil society. The 
brevity of the Green Paper and the narrow focus of the 
issues presented therein belie the complexity of the topic. 
What civil society is and how it should engage in public 
policy development are being fervently debated at both 
United Nations (UN) and European Union (EU) level and 
views and understandings are evolving rapidly.
EU and civil society
In Europe civil society has had a formal voice since the 
establishment of the European Economic and Social 
Council (EESC) under the 1957 Treaty of Rome.2 In 
1994, under the EU Treaty, a Committee of the Regions 
(CoR) was established to give a voice to regional 
and local authorities.3 In 2001, in preparation for EU 
enlargement, the European Commission launched 
a white paper on European governance, seeking to 
enhance democracy and increase the legitimacy of the 
EU institutions.4 This white paper identified a number of 
ways of strengthening the role of civil society in relation 
to the work of the European Commission, including 
establishing minimum standards for consultation,5 setting 
up a database accessible to the public which lists the civil 
society organisations (CSOs) involved in consultations,6 
and using the Internet to collect and analyse reactions 
in the market place for use in the EU’s policy-making 
process.7 In 2006 the European Commission launched an 
open public consultation on a new initiative on European 
transparency, seeking, among other things, feedback on 
the Commission’s minimum standards for consultation.8  
These initiatives highlight a number of questions relevant 
to the involvement of civil society in EU drugs policy.9 For 
example:
 
•   Representivity: How are CSOs to be chosen and what 
contribution can they make? Who should act as the 
gatekeeper and how? Acknowledging the diversity 
of views and approaches among CSOs in the drugs 
field, the Green Paper states that the European 
Commission will ‘select members for the Forum 
on the basis of an open call, after it has received 
and analysed reactions to the Green Paper’ (p. 8). 
The Paper states that representation of different 
stakeholders and different policy options should 
be balanced and that membership of the Forum 
should be for a fixed term, and proposes some 
preliminary selection criteria, including credibility 
and representativeness.
Civil society to have role in EU drugs policy
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Civil society and EU drugs policy (continued)
•   Democratic Legitimacy: How will the European 
Commission balance policy input from civil 
society against input from the democratically-
elected governments of member states or from 
other democratic sources such as regional or 
local authorities? The Green Paper states that the 
‘consultations with civil society should not replace 
or duplicate the existing debate between civil 
society and national or local governments. The 
focus should be on European added value’ (p. 8, 
underlining in original).
•   EU Decision-Making Procedures: The Green Paper 
does not address the question of whether and 
how civil society might interact with other EU 
institutions involved in making drug-related policy, 
e.g. the European Council and the European 
Parliament. For example, in the area of supply 
reduction, including drug trafficking and organised 
crime, it is the European Council, rather than the 
European Commission, that makes policy decisions. 
UN and civil society
Article 71 of the 1945 UN Charter mandates a 
consultative role for civil society in relation to the UN’s 
Economic and Social Council (ESC).10 In turn, the 
UN Office for Drugs and Crime (UNODC), which is 
accountable to the ESC, promotes strong partnerships 
with CSOs in countering the global drug abuse and 
crime problem.11 In recent years the UN has embarked 
on an extensive programme of organisational reform, 
including reviewing the role of civil society.12 The 
review of the role of civil society in relation to the UN 
addresses many of the same issues as the EU. Two 
additional areas relevant to the role of civil society in 
relation to EU drugs policy are:
•   Operational Systems and Procedures:  How are 
CSOs which participate in policy making to be 
resourced and supported in their Commission-
related work? What mechanisms are needed to 
support the CSOs and co-ordinate their work with 
that of the European Commission? What protocols 
need to be developed to govern access to the 
Commission and ensure appropriate interactions 
and information flows between Commission 
personnel and CSOs?  While not addressed in the 
Green Paper, these matters have been considered 
as part of the UN reform process.13
•   Governance:  Perhaps the most contentious 
question about the role of civil society in relation 
to policy making is that of its role in respect 
of decision making – what responsibilities will 
be assigned to CSOs, and to whom shall they 
be accountable? The European Commission’s 
Green Paper indicates that CSOs will ‘support’ 
policy formulation and implementation, provide 
practical advice, inform and network, but not 
decide. The chair of the UN Panel of Eminent 
Persons, Fernando Henrique Cardoso, put the 
case as follows:  ‘The legitimacy of civil society 
organizations derives from what they do and not 
from whom they represent or from any kind of 
external mandate. In the final analysis, they are 
what they do. The power of civil society is a soft 
one. It is their capacity to argue, to propose, to 
experiment, to denounce, to be exemplary. It is 
not the power to decide.’14 (Brigid Pike)
 
1.    Released on 26 June 2006 the Green Paper on 
the role of civil society in drugs policy in the 
European Union (COM (2006) 316 final) seeks 
responses by 30 September 2006 to a number 
of questions set out on page 9 of the document. 
Submissions should be sent to:  European 
Commission, Directorate General for Justice, 
Freedom and Security, Unit C2 – Anti-Drugs 
Policy Co-ordination Unit, LX 46 1/88 – 1049 
Brussels, Belgium. Email: JLS-drugspolicy@
ec.europa.eu . Fax: 00 322 295 32 05.
2.  See www.eesc.europa.eu/
3.   See www.cor.europa.eu/
4.    See ‘European governance’ COM (2001) 428 
final. Retrieved 28 July 2006 at www.ec.europa.
eu/governance/ 
5.    See ‘Towards a reinforced culture of consultation 
and dialogue – General principles and minimum 
standards for consultation of interested parties by 
the Commission’ COM (2002) 704 final. Retrieved 
28 July 2006 at www.ec.europa.eu/civil_society/ 
6.    See CONNECS at www.ec.europa.eu/civil_society/ 
7.    See ‘Interactive policy making’ COM (2001) 1014 
final, and also www.ec.europa.eu/yourvoice/  
8.    See ‘European transparency initiative’ COM 
(2006) 194 final. Retrieved 28 July 2006 at www.
ec.europa.eu/transparency/ 
9.   J Almer and M Rotkirch (2004) European 
Governance – An overview of the Commission’s 
agenda for reform (Stockholm: Swedish Institute 
for European Policy Studies) provide a useful 
account and assessment of the issues arising out of 
the implementation of the 2001 White Paper on 
European governance in relation to civil society. 
Retrieved 28 July 2006 at www.sieps.se
10. See www.un.org/issues/civilsociety/ 
11.  See www.unodc.org/unodc/en/ngos_and_civil_
society.html 
12.  In June 2004 a Panel of Eminent Persons, 
appointed by the UN to assess and draw lessons 
from UN interaction with civil society with a view 
to enhancing interaction between them, released 
its 83-page report, ‘We the peoples: civil society, 
the United Nations and global governance’ 
(A/58/817). The following September the UN 
Secretary General, Kofi Annan, published his 
response, ‘Report of the Secretary General in 
response to the report of the panel of eminent 
persons on United Nations–Civil society relations’ 
(A/59/354). Documents retrieved 28 July 2006 at 
www.un.org/reform/civil-society.html 
13.   See J Clark and Z Aydin (2003) ‘UN system 
and civil society – An inventory and analysis of 
practices’. Background paper for the Secretary-
General’s panel of eminent persons on United 
Nations relations with civil society. Retrieved 28 
July 2006 at www.un.org/reform/civil-society.html 
14.   See F H Cardoso (2003) ‘Civil society and global 
governance.’ Contextual paper prepared by the 
Chairman of the high-level panel on UN–civil 
society. Section 4.2. Retrieved 28 July 2006 at 
www.un.org/reform/civil-society.html 
In recent years 
the UN has 
embarked on 
an extensive 
programme of 
organisational 
reform, 
including 
reviewing the 
role of civil 
society.
The power of 
civil society is 
a soft one. It is 
their capacity 
to argue, to 
propose, to 
experiment, to 
denounce, to 
be exemplary. 
It is not the 
power to 
decide. 
The first strategic plan of the Northwest Regional 
Drugs Task Force (NWRDTF), entitled Co-ordinating 
action around drug and youth alcohol problems, was 
published in June 2005.1 
The NWRDTF was established in 2003 and covers 
counties Donegal, Sligo and Leitrim and the north 
western portion of county Cavan.  Development 
of the plan involved extensive consultation with 
stakeholders which included one-to-one interviews, 
a series of group workshops and review sessions.  
Background research was also carried out on existing 
services, drug prevalence and the population 
distribution of the North West. 
The strategic aim of the plan is: ‘to reduce the 
negative impact of drug misuse and underage 
drinking upon the individual and society in the 
region through co-ordinated and targeted actions at 
regional and local levels.’ The strategic objectives of 
the plan are grouped under the following headings: 
awareness; co-ordination; communication; direct 
actions; and advocacy.
The NWRDTF identified actions based upon the 
agreement that all actions should be tailored to meet 
the specific needs of the North West. These needs are:
•   The population distribution of the region and the 
need to restructure the group to accommodate the 
geographical spread.
•   The need to maintain or reduce the low level of 
drug prevalence in the region.
•   The impact of Northern Ireland (particularly Derry) 
on the drug culture in the North West.
•   The level of polydrug use among drug users. 
•   The level of underage drinking, which has been 
identified as a significant problem throughout the 
region.
•   The degree to which the drug culture and 
underage drinking have become intertwined in 
recent years.
The action plan drawn up by the NWRDTF is 
organised according to the four pillars of the 
National Drugs Strategy and also includes a section 
on operational actions. The actions are described in 
detail, allocated high, medium or low priority and 
the stakeholders responsible for implementing them 
are listed. The table below provides a summary of the 
high-priority actions. 
Operational actions 
•   Recruit NWRDTF Co-ordinator, Development 
Worker and Administration Support.
•   Take account of operating costs (for example, 
rent, insurance, and financial and legal fees).
•   Expand membership of NWRDTF and sub-
committees to encourage knowledge-based 
representation.
•   Source external providers with experience in 
community-based organisations to provide on-
going training and support to the NWRDTF and 
its sub-committees to ensure they operate in an 
effective manner.
•   Establish and operate county-based and interest-
based sub-committees of the NWRDTF.  
•   Promote the NWRDTF as the regional body 
for co-ordinating all illicit drug and underage 
drinking initiatives and as the central contact 
point in the region.
•   Review NWRDTF structures and validate initiatives 
and programmes.
Supply reduction
•   Establish a sub-committee with the authority to 
initiate actions aimed at supply reduction.
•   Support the development of a referral scheme 
between the Garda Síochána and service 
providers for underage drinking and drug-related 
offenders.
Education
•   Provide public training and information sessions 
for community groups to assist in developing 
appropriate responses to local problems.  
•    Work closely with communities to identify their 
concerns and issues relating to illicit drug use 
and underage drinking and to assist in finding 
solutions.
•   Establish protocols to co-ordinate inter-
agency activities (interventions in schools and 
communities).
•   Undertake a publicity campaign informing the 
public and community groups of the role and 
functions of the NWRDTF.
•   Design and maintain a single website for the 
NWRDTF, including sub-committees and special 
interest groups.
•   Initiate a film programme, aimed at transition 
year students, inviting submissions of films 
dealing with illicit drug use and underage 
drinking.  
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Northwest Regional Drugs Task Force 
Strategic Plan 2005–2008
Development 
of the plan 
involved extensive 
consultation with 
stakeholders 
which included 
one-to-one 
interviews, a 
series of group 
workshops and 
review sessions.  
The action plan 
drawn up by 
the NWRDTF 
is organised 
according to the 
four pillars of the 
National Drugs 
Strategy and also 
includes a section 
on operational 
actions. 
•   Develop programmes aimed at pubs and night 
clubs to address the intertwined nature of illicit 
drug use and underage drinking.  
•   Identify effective methods of communication 
for individuals and communities responding to 
illicit drug use and underage drinking at the 
local level.
•   Develop and publish regionally relevant, local 
information on illicit drug use and underage 
drinking.
Treatment and rehabilitation
•   Publish a North West Region handbook 
for those affected by illicit drug use and 
underage drinking, providing:
 -  A step-by-step guide to accessing help 
locally;
 -  Contact and service information at local/
county level.
•   Help secure funding for programmes aimed at 
the reduction of illicit drug use and underage 
drinking.
•   Establish:
 -  A small-grant fund to provide funding to 
evidence-based community and voluntary 
projects relating to illicit drug use and 
underage drinking;
 -  A Youth Alcohol and Drug Service in Leitrim 
on a pilot basis;
 -  A relapse-prevention programme to equip 
participants with a range of skills, including 
assertiveness, problem solving and creativity.
•   Support: 
 -  The establishment of a urine analysis 
protocol between the Probation and Welfare 
Service and HSE NW;
 -  An increase in the number of support 
workers and level of resources available to 
those working with young people at risk 
and/or outside mainstream education;
 -  Initiatives in the region that will impact on 
awareness, transmission, treatment and 
management of blood-borne viruses;
 -  The provision of drug and alcohol 
counsellors to the Courts Service, in 
partnership with Probation and Welfare;
 -  The development of residential and in-
patient services (for example, an under-
18s alcohol and drug detoxification and 
treatment facility);
 -  The HSE NW in developing a Court Alcohol 
and Drug Programme in the region 
dedicated to under-18s.
Research
•   Conduct research into levels of misuse in the 
North West and provide access to up-to-date 
information.
•   Work with other agencies to identify more 
effective means of extracting and recording 
data on levels of misuse in the North West 
(for example the Coroners Court and HIPE).
(Sarah Fanagan)
1.  Northwest Regional Drugs Task Force (2005) 
Co-ordinating action around drug and youth 
alcohol problems: Strategic Plan 2005–2008. 
Ballyshannon: Northwest Regional Drugs Task 
Force.
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NWRDTF Strategic Plan 2005-2008 (continued)
In October 2006 the Health Research Board will 
publish Overview 4, which describes what is known 
about blood-borne viral infections among drug 
users in Ireland.1 The data pertaining to injecting 
drug users are presented where possible, and 
where the data are not analysed by injecting status 
or where injecting status is not ascertained, the 
data on all drug users are presented. 
The analysis presented in this Overview is based 
on disease notifications reported to the Health 
Protection Surveillance Centre (formerly known as 
the National Disease Surveillance Centre) during 
the period 1995 to 2005 and on ad hoc research 
studies. 
The main observations and their implications 
are: 
The number of newly diagnosed cases of HIV 
among injecting drug users increased in 1999 
and to date has remained at a higher level than 
in the early nineties, while the number of new 
AIDS cases diagnosed decreased. Around one-
tenth of injecting drug users in drug treatment 
are HIV positive. Age, injecting practices and 
sexual practices are associated with HIV status. The 
increase in HIV infections over the last five years 
requires investigation. HIV treatment is available to 
injecting drug users through genito-urinary medical 
units and infectious disease clinics in Ireland. In 
2003, a study reported that a number of stable 
Overview of blood-borne viral infections 
among injecting drug users in Ireland, 
1995 to 2005
injecting drug users were suitable for treatment, 
but were not receiving treatment at the time of the 
study. Two studies demonstrated that decentralised 
treatment at drug treatment centre level achieved 
high uptake and compliance with HIV treatment. 
Just under one-fifth of injecting drug users in 
treatment have ever been infected with hepatitis 
B and approximately 2% are chronic cases. Age, 
injecting practices and sexual practices are linked 
to hepatitis B status. The uptake and completion 
rates of hepatitis B vaccination are much higher 
in the HSE South Western Area (56%) and in 
Drug Treatment Centre Board (86%) cohorts for 
the period 2001 to 2003 than those reported in 
prisoners or at general practice in Ireland between 
1998 and 2001. This possibly indicates an increase 
in hepatitis B vaccine coverage in recent years. 
There are no published data on the coverage of 
hepatitis B vaccine among injecting drug users 
outside the HSE Eastern Region. It is important to 
ensure that hepatitis B vaccine is administered as 
early as possible in a drug user’s career; therefore, 
needle exchange and low-threshold methadone 
services require facilities to deliver this intervention 
on a daily basis. 
Around 70% of injecting drug users attending 
drug treatment tested positive for antibodies to 
the hepatitis C virus. Injecting practices and prison 
history are associated with hepatitis C status. 
There are seven specialist hepatology centres for 
adults and one for children in Ireland. A number 
of studies demonstrated low rates of access to and 
uptake of treatment for hepatitis C among injecting 
drug users. Two small studies demonstrated that 
a decentralised approach to initial assessment at 
general practice level and hepatitis C treatment 
at drug treatment centres achieved higher uptake 
and compliance rates than the current centralised 
approach. 
Little has been published in Ireland on the 
prevalence of co-infection with HIV and/or hepatitis 
B and/or hepatitis C. The two national prison 
surveys in the late nineties presented data on co-
infection among prisoners. These data indicated 
that approximately one-fifth of prisoners testing 
positive for hepatitis C were also infected with 
either hepatitis B or HIV. Up-to-date information is 
required. 
Both HIV co-infection and, independently, high 
rates of alcohol consumption among those infected 
with hepatitis C are associated with more rapid 
disease progression and higher death rates. 
The principles of expanded and accessible harm 
reduction measures are documented in both the 
AIDS Strategy 2000 and the Mid-Term Review 
of the National Drugs Strategy and will lead to 
synergistic actions to stem the current increase in 
new HIV cases among injecting drug users. The 
publication of the HSE Eastern Region’s hepatitis C 
strategy is awaited. 
Newly diagnosed HIV cases are reported directly to 
the Health Protection Surveillance Centre (HPSC) 
through a case-based, extended surveillance system 
and staff at the HPSC collate these data on a six-
monthly basis. Up to 2005, information on risk 
factors was not included in the data recorded on 
newly diagnosed cases of hepatitis B and hepatitis 
C, which makes it difficult to monitor the number 
of newly diagnosed cases of these infectious 
diseases among injecting drug users. It also means 
that Ireland has been unable to provide data to 
the European Monitoring Centre for Drugs and 
Drug Addiction on the incidence of hepatitis B and 
hepatitis C among injecting drug users. Action 39 
of the European Union Drugs Action Plan requires 
member states to comply with the requirements of 
the key indicators to measure the drug situation. 
The incidence and prevalence of HIV, hepatitis 
B and hepatitis C among injecting drug users is 
one of the five key indicators. In recent years, 
the HPSC has improved the reporting of newly 
diagnosed cases of hepatitis B and hepatitis C. In 
2006, hepatitis B data by risk factor status will be 
published. 
There are a number of areas where further research 
is required. The data presented in this Overview 
indicate the need to record the risk factor status 
of newly diagnosed cases of hepatitis C. There 
is a need to set up a register to quantify the 
incidence and prevalence of hepatitis C among 
all heroin and cocaine users, including those who 
are in harm reduction and treatment services. 
The register should also permit the assessment of 
main risk factors, treatment uptake and outcomes. 
Strategies to increase uptake of and compliance 
with HIV and hepatitis C therapy in both prison 
and community settings need to be implemented 
and monitored. The medical consequences of and 
interventions required to deal with hepatitis C 
among injecting drug users need to be estimated. 
A system to monitor the national hepatitis B 
vaccine uptake is required to estimate coverage 
among prisoners, injecting drug users and sex 
workers. The effectiveness of needle exchange, 
opiate detoxification and opiate maintenance 
programmes in stabilising and reducing the 
incidence of hepatitis C needs to be quantified. 
(Jean Long)
1.  Long J (2006) Blood-borne viral infections among 
injecting drug users in Ireland 1995 to 2005. 
Overview 4. Dublin: Health Research Board.
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Overview of blood-borne viral infections (continued)
Around 70% of 
injecting drug 
users attending 
drug treatment 
tested positive for 
antibodies to the 
hepatitis C virus. 
There is a need to 
set up a register 
to quantify the 
incidence and 
prevalence of 
hepatitis C among 
all heroin and 
cocaine users, 
including those 
who are in 
harm reduction 
and treatment 
services. 
HIV (subsequently known as HIV1) was identified 
in 1981 and HIV2 was identified in 1986. The 
virus attaches itself to the CD4 particle of the T-
lymphocytes. These T-lymphocytes co-ordinate 
the body’s immune response. HIV may lead to a 
condition known as acquired immunodeficiency 
syndrome (AIDS). This condition generally occurs 
when the CD4 count is below 200 per millilitre and 
is characterised by the appearance of opportunistic 
infections. Such infections take advantage of a 
weakened immune system. The HIV virus is found 
in all body fluids and is transmitted via sexual 
intercourse (both heterosexual and homosexual), 
mother to foetus and baby, infected blood and blood 
products and procedures with unsterile needles, 
syringes and skin-piercing instruments. Best evidence 
available to date indicates that once an individual is 
infected he or she remains infected for life. 
Voluntary linked testing for antibodies to HIV has 
been available in Ireland since 1985. By the end 
of 2005, there were 4,082 diagnosed HIV cases 
in Ireland, of which 1,270 (31%) were probably 
infected through injecting drug use.1 
Figure 1 presents the number of new cases of HIV 
among injecting drug users, by year of diagnosis, 
reported in Ireland; data from 1982 to 1985 
were excluded from the figure as these four years 
were combined in the source records. The data 
presented in Figure 1 are based on data reported 
to the Department of Health and Children,2 the 
National Disease Surveillance Centre3 and the Health 
Protection Surveillance Centre.1, 4 Kelly and Clarke5 
reported a fall in the number of HIV cases among 
injecting drug users between 1994 and 1998, with 
about 20 cases per year compared to about 50 cases 
each year in the preceding six years. In 1999, there 
was a sharp increase in the number of cases among 
injecting drug users, which continued into 2000, 
with 69 and 83 new cases respectively.6 Between 
2001 and 2003 there was a decline in the number 
of new injector cases (38, 50 and 49 respectively) 
when compared to 2000 but the number was higher 
than in 1998. In 2004, once again there was an 
increase (to 71 cases) in the number infected through 
injecting drug use compared to the preceding three 
years. In 2005 there were 66 cases infected through 
injecting drug use. It was difficult to interpret the 
trend due to the relatively small numbers diagnosed 
each year, so a smoother curve (red line in Figure 
1) was calculated using a rolling centred three-year 
average. This curve presents an increase in the annual 
number of HIV cases in 1999; this higher number of 
cases was sustained between 2000 and 2004. This 
indicates a true increase in the number of cases. 
Of the 66 new HIV cases among injecting drug 
users reported to the Health Protection Surveillance 
Centre in 2005, 37 were male and 29 were female 
and the average age was 30.5 years. Of the 60 cases 
for whom place of residence was known, 55 lived in 
the HSE Eastern Region. The authors of the report on 
the 2004 data highlighted the need to continue to 
promote the use of harm reduction measures among 
injecting drug users. (Jean Long)
1.  Health Protection Surveillance Centre (2005) Newly 
diagnosed HIV infections in Ireland: quarters 3 & 4 
2004, and 2004 annual summary. Dublin: Health 
Service Executive. 
2.  O’Donnell K, Cronin M and Igoe D (2000) Review 
of the epidemiology of AIDS in Ireland 1983–1999. 
Dublin: National Disease Surveillance Centre. 
3.  National Disease Surveillance Centre (2004) Newly 
diagnosed HIV infections in Ireland. quarters 3 & 4 
2003, & 2003 annual summary. Dublin: National 
Disease Surveillance Centre. 
4.  Health Protection Surveillance Centre (2006) Newly 
diagnosed HIV infections in Ireland: quarters 3 & 4 
2005, and 2005 annual summary. Dublin: Health 
Protection Surveillance Centre. 
5.  Kelly GE and Clarke SM (2000) Has there been 
a turning point in the numbers of AIDS and HIV 
antibody positive cases in Ireland? Irish Journal of 
Medical Science, 169(3): 183–186.
6.  National Disease Surveillance Centre (2001) HIV 
and AIDS: updated 2000 figures. Dublin: National 
Disease Surveillance Centre. 
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New data on the incidence of HIV
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Figure 1  Actual number and rolling average number of new cases of HIV among injecting drug 
users, by year of diagnosis, reported in Ireland, 1986 to 2005 
Adapted from data reported to the Health Protection Surveillance Centre
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Special initiative: working together to 
reduce the harms caused by alcohol misuse
Sustaining Progress, the agreement between Government and the 
social partners, set out ten special initiatives to be progressed in its 
lifetime; these were issues that required ‘mobilisation of a range 
of resources across sectors, organisations, and individuals, and at 
different levels of government’. One of the issues selected was 
alcohol and drug misuse. 
To progress this special initiative, the Working Group on Alcohol 
Misuse was established in July 2005. The Group was chaired by 
Peter Cassells and included representatives from six government 
departments, the Irish Congress of Trade Unions, IBEC, the Health 
Service Executive, An Garda Síochána and a number of youth 
groups. The Group also consulted with relevant stakeholders not 
directly represented. The aim of the Group was to agree on a 
programme of actions to deliver targeted results in relation to 
the three specific areas of underage drinking, harmful (binge) 
drinking and drink driving. It concentrated on the potential for 
effectively mobilising State and other organisations and the social 
partners around a programme of actions that would contribute to 
a reduction in alcohol misuse.
While the Group considered the three specific areas, its final report1 
sets out a single strategy containing 29 actions under 11 headings, 
as follows:
Local community responses
•   Establish at least four community mobilisation projects2 by the 
end of 2006.
 
Treatment intervention services
•   Set up one pilot screening and brief intervention project in 
each of the community mobilisation project areas by the end of 
2006.
•   Develop a national screening and brief intervention protocol for 
appropriate healthcare settings by the end of 2007.
•   Prepare an extended early intervention plan for the existing 
juvenile liaison scheme by the end of 2006.
•   Examine the benefits and potential of mandatory alcohol 
awareness and rehabilitation programmes for those convicted 
of drink-driving offences; the plan will be prepared by the end 
of 2006. 
•   Examine the feasibility of developing counselling services for 
those affected by drink-driving accidents by the end of 2007. 
Awareness and education interventions
•   Continue the roll-out and development of the Social, Personal 
and Health Education curriculum in schools, with special 
emphasis on the community mobilisation project areas.
•   Develop appropriate education initiatives in out-of-school 
settings.
•   Increase parents’ awareness of alcohol use among children 
through the provision of appropriate information, such as the 
booklet Straight Talking, during 2006.
•   Train community and youth workers on alcohol issues, using 
the Code of Ethics which will be published in 2006 by the 
National Youth Work Advisory Committee. The training will be 
implemented in 2007.
•   Enhance local road safety initiatives in co-operation with local 
communities during 2006 and 2007.
•   Increase public awareness within communities on the harms 
associated with alcohol use through media campaigns from 
2006 to 2010.
Alternative facilities
•   Develop and promote at least one alcohol-free recreation facility 
in each of the community mobilisation project areas by early 
2007.
•   Involve young people in the management structure and day-to-
day management of the facilities by early 2007.
•   Promote responsible approaches to alcohol by sporting 
organisations at local level from 2006 onwards. 
Compliance and enforcement
•   Support more visible enforcement and compliance with liquor 
licensing legislation in each of the community mobilisation 
project areas in 2006 and 2007.
•   Promote responsible serving and trading programmes in each of 
the community mobilisation project areas in 2006 and 2007.
•   Improve the security details for the Garda National Age Card by 
2007 in order to reduce forgery. 
Workplace
•   Develop guidelines to facilitate the development of alcohol 
misuse policies for the workplace in 2006.
Below-cost selling
•   Prohibit below-cost selling of alcohol by March 2006.
Off-trade
•   Develop a code of practice with the off-trade sector and 
legislation to address specific areas of concern by the end of 
2007
Alcohol advertising
•   Propose additional representation from the social partners on 
the monitoring body for the Voluntary Code on Advertising. The 
proposal will be considered in 2006.
 
Drink driving
•   Introduce random breath testing.
•   Reduce the blood alcohol level from 0.8mg% to 0.5mg%.
•   Keep under review the question of setting lower blood alcohol 
level for provisional drivers.
•   Promote high visibility enforcement of traffic laws.
•   Introduce administrative alternative to court (though 
disqualification should remain a deterrent).
•   Restructure provisions to ensure that the period of 
disqualification for a drink-driving offence cannot be reduced on 
appeal.
 
Labelling
•   Establish a group to consider the information to be included on 
the labels of non-draft alcohol products in 2006. 
This report does not give details of budget provision for the 
implementation of any of these actions and, while it suggests 
some possible sources of support and mentions monitoring 
arrangements, it makes no clear commitment to ensuring that the 
actions are completed. (Jean Long)
The new social partnership agreement, Towards 2016, is discussed 
on p. 7.
1.  Sustaining Progress Special Initiative: working together to reduce 
the harms caused by alcohol misuse (2006) http://www.dohc.
ie/publications
2.  The authors describe community mobilisation projects (CMPs) as 
a comprehensive response involving a wide range of individuals, 
agencies and organisations which come together when an issue 
is too big for one sector to tackle alone.
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Drugnet Ireland survey results
We asked you, our readers, to tell us a little about 
yourselves and what you think about Drugnet 
Ireland. We sent out 1,780 short survey forms and 
freepost reply envelopes with the Spring issue. The 
response rate was lower than we had hoped –  we 
received  227 (13%) completed forms. Thank you 
to all of you who took the time to complete and 
return the questionnaire. What we learned from 
your replies will influence our decisions about the 
content and development of Drugnet Ireland.
Key survey findings
We received forms from respondents working in a 
wide variety of occupations and settings.  Seventeen 
categories of workplace were represented; the 
highest number of responses came from local 
drugs projects or community-based services (25%), 
followed by drug treatment centres (19%).
We explored readers’ preferences. The areas in 
which people had the most interest, and would like 
covered in more depth, were: social consequences, 
treatment, health consequences and problem 
alcohol use. One new topic suggested by a 
small number of readers was ‘user involvement’. 
In previous issues of Drugnet Ireland, we have 
summarised research conducted by user groups 
and will continue to do so in the future.  
We ascertained the readers’ experience of Drugnet 
Ireland (see Figures 1–3):
•   93% reported that Drugnet Ireland was an 
important source of information on the drugs 
situation in Ireland. 
•   91% found that the content was relevant to 
their work.
•   34% often discussed the contents with their 
colleagues, while more than half (57%) 
occasionally discussed the contents.
•   46% reported that the detail of articles was 
adequate, although 45% reported that articles 
can be too detailed. 
•   Almost all respondents (99%) reported that the 
presentation of articles was clear.
•   88% found the use of graphics and tables was 
helpful; however, 10% found them confusing at 
times. 
We also asked how often regular features in 
Drugnet Ireland were read and whether information 
from these features was used in work.  There were 
many missing answers for the latter question (over 
40%) but both sets of answers followed a similar 
pattern. The items ‘In brief’, ‘New publications’ 
and ‘Upcoming events’ were read ‘often’ by over 
65% of readers. Around two-fifths of respondents 
said that they used the information in these 
features in the course of their work.  
Finally, we asked how respondents would prefer to 
receive the newsletter.1
•   54% of respondents are aware that an electronic 
version of Drugnet Ireland exists.  
•   4% read the electronic version.  
•   32% of respondents would prefer the electronic 
version to the print one. (Mary Dunne)
1.  An electronic version of Drugnet Ireland is available 
on the National Documentation Centre on Drug 
Use website, www.hrb.ie/ndc. A PDF version is on 
the Health Research Board site www.hrb.ie.
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Figure 1   Drugnet Ireland is important as a 
source of information (225 respondents)
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Figure 3   Drugnet Ireland contains adequate 
detail in articles (226 respondents)
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Figure 2   Drugnet Ireland is discussed with 
colleagues (224 respondents)
The areas in 
which people had 
the most interest, 
and would 
like covered in 
more depth, 
were: social 
consequences, 
treatment, health 
consequences  
and problem 
alcohol use.
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The National Documentation Centre on 
Drug Use 
 
New Directory of training 
courses
The National Documentation Centre on Drug 
Use has published a new Directory of courses and 
training programmes on drug misuse in Ireland for 
individuals and agencies interested in developing 
their knowledge, skills and capacity in this field.  
The only other resource of this kind was produced 
by the Department of Tourism, Sport and 
Recreation in 1999. Course details are primarily 
based on responses to a request for information 
from course co-ordinators in Drugnet Ireland, issue 
16. We also contacted many training institutes and 
organisations directly.  
The Directory lists a range of training available, 
from single sessions to courses lasting up to two 
years. Obviously, the depth of coverage of the 
issues varies considerably according to the length 
of the course and the level at which it is aimed. 
There are also variations in the training methods 
and in the underlying principles and approaches to 
issues in drug misuse.  
Different courses are aimed at different target 
groups. Some courses are open to anyone in the 
community who is interested in the issue; others 
are aimed at those whose work brings them into 
contact with drug-related issues; and some are 
aimed at specific groups. The majority of courses 
listed in the Directory do not stipulate formal 
educational attainments as entry requirements, 
although a number of more advanced courses 
do require participants to have some previous 
knowledge and understanding of relevant issues.
The Directory does not assess or provide 
information about the quality or relevance of 
any of the courses listed. Instead, we present 
information as supplied by the course co-ordinators 
on course length, assessment, qualifications and 
accreditation.
Twenty-eight providers sent us information about 
69 courses and we divided these into five sections:
A   Short courses (less than 20 hours of course 
time) providing basic information and/or raising 
awareness of drug misuse among a general 
target audience, or developing skills of those 
working in the field of drug misuse – 37 entries
B   Longer courses providing information, raising 
awareness and developing skills among those 
whose paid or voluntary work brings them into 
contact with drug misuse – 16 entries
C   Courses leading to a professional or academic 
qualification (at diploma level or higher) in the 
field of drug misuse – 9 entries
D   Courses in drug misuse for young people – 3 
entries
E   In-service training for professionals and other 
vocational groups working in the field of drug 
misuse or related areas – 4 entries
Most course providers are based in Dublin (68%), 
others are in counties Carlow, Wexford, Waterford, 
Tipperary, Kildare, Meath, Offaly, and Cavan. A 
small number of courses are offered outside these 
locations but, while the midlands, northeast and 
southeast are well represented, large parts of the 
country do not have or did not submit courses.  
One online course, suitable for home-learning, is 
included.
The information was gathered over a short 
period of time. Inevitably, some agencies 
providing courses and training in drug misuse 
were overlooked, while others were unable to 
respond in time. New courses are continually 
being developed. We hope, therefore, to update 
this directory at least annually. Please consult our 
website, www.hrb.ie/ndc, for the most up-to-date 
edition. (Mary Dunne)
 
Course co-ordinators who wish to revise an 
existing entry or include a new course in the 
next edition of the Directory may request an 
application form from mdunne@hrb.ie
The Directory lists 
a range of training 
available, from 
single sessions to 
courses lasting up 
to two years.
We present 
information  
as supplied  
by the course co-
ordinators  
on course length, 
assessment, 
qualifications and 
accreditation.
The Exchange on Drug Demand Reduction Action 
(EDDRA) column has appeared in the past 15 issues 
of Drugnet Ireland. The purpose of this column 
is to inform readers about the EDDRA database 
as a knowledge resource on good practice in the 
field of drug demand reduction and to highlight 
examples of good practice. This present column 
is taking a slightly different approach, in that its 
purpose is to highlight the upcoming revision of 
the EDDRA database being co-ordinated by the 
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA). This revision will inevitably 
mean changes in reporting practices to the EDDRA 
database, as the main aim of the revision is to 
further develop EDDRA as a tool for collecting, 
storing and disseminating examples of science-
based practice in the field. Science-based practice 
will include interventions that are theoretically 
based and have been evaluated for effectiveness, 
meaning that the evaluation has identified what 
works, for whom and under what conditions. In 
some cases, these evaluations are referred to as 
outcome or impact evaluations.
EDDRA was established in 1996 to collect, store 
and disseminate information on good practice 
in demand reduction throughout the EU, with 
the aim of promoting the role of evidence-based 
practice and an evaluation culture within the field. 
Ten years on, and with a renewed focus on what 
constitutes evidence-based practice within the EU 
and the role of the EMCDDA in disseminating this 
information, a decision has been taken to review 
the current structure and operation of EDDRA.  
From the outset, the Drug Misuse Research 
Division (DMRD), as the Irish Focal Point for 
EMCDDA activities, has been one of the main 
providers of information to EDDRA, with data on 
over fifty interventions submitted for inclusion 
on the database. This information is presented 
in a standardised format that includes aims and 
objectives, evaluation indicators and evaluation 
results. The interventions are judged to be well 
designed and have been evaluated and thus satisfy 
the main criteria for inclusion. However, like most 
of the interventions in EDDRA, there are questions 
regarding the quality of the evaluations and 
whether they can be referred to as science based. 
For example, the majority of interventions have 
not been evaluated to determine their effectiveness 
in producing an intended or expected result. 
Instead, evaluations have tended to examine 
how the intervention is being implemented and 
whether the target group is being successfully 
reached. The usual methods employed are semi-
structured interviews with staff, and in some cases 
with participants. There is nothing wrong with 
this type of evaluation, indeed it is necessary to 
establish the status of interventions that have 
been running for at least one year. We know little 
about the effectiveness of interventions that are 
seeking to reduce the demand for drugs in Ireland. 
Even where evaluations have reported on positive 
outcomes, such as individuals remaining drug free 
or progressing to education or employment, there 
is little evidence to show how this was achieved 
and under what conditions it could be replicated. 
As noted earlier, there is a move within the 
EMCDDA for a more targeted focus on identifying 
and disseminating information on science-based 
practice in the field, and it is envisaged that the 
EDDRA database will be refined to play a role in 
these activities, which are influenced by the EU 
Drugs Action Plan 2005–2008. The next steps in 
the revision process are a technical meeting on 13 
September 2006 in Lisbon and further discussion 
at the EDDRA managers’ meeting on 3–4 October 
2006. Drugnet Ireland will keep readers informed of 
these developments as they proceed.  
(Martin Keane) 
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The EDDRA column
In brief
On 18 May 2006 the Special Residential Services 
Board (SRSB) held its annual conference on the 
theme of ‘Stepping Out: Young People Leaving Care/
Custody’. Presentations were given on the legislative 
and policy context and on the work of Crosscare, 
Extern Ireland, Life Centre, Lilac House, the Probation 
and Welfare Service, the Scottish Throughcare and 
Aftercare Forum, and Trinity House School. www.
srsb.ie 
 
On 25 May 2006 the report Counted in 2005 was 
launched by Noel Ahern TD, Minister of State for 
housing and urban renewal. The report presents 
the results of the third periodic assessment of 
homelessness in the Dublin area. Conducted every 
three years, the assessment shows that, among 
other things, the number of people sleeping rough 
increased from 1999 to 2002, but decreased 
between 2002 and 2005, with a significant overall 
decrease of 33% from 1999 to 2005.  
www.homelessagency.ie 
In May 2006 the Irish Pharmaceutical Union (IPU) 
called on the Health Service Executive to develop 
a dedicated liaison service for pharmacies outside 
Dublin that participate in the Methadone Treatment 
Scheme. This service would provide community 
pharmacists with a point of contact if they encounter 
difficulties when dispensing methadone to patients. 
The IPU is also calling for more protection for 
pharmacies from attacks and tougher action in the 
Courts against individuals who raid pharmacies. 
www.ipu.ie 
On 1 June 2006 an Independent Evaluation 
of the RAPID Programme was published. The 
report indicates that the RAPID programme has 
contributed substantially to identifying the needs 
There is a 
move within 
the EMCDDA 
for a more 
targeted focus on 
identifying and 
disseminating 
information on 
science-based 
practice in the 
field.
of disadvantaged communities, bringing forward 
important local projects in response to those needs 
and establishing structures that have been effective 
in facilitating local development activity. On the 
negative side, the evaluators identified a general 
weakness with regard to strategic planning in some 
areas, variations in the level of interaction with 
the local implementation of the programme by 
representatives of key State agencies, and difficulty 
in securing funding for particular types of projects, 
for example, education, training and employment. 
www.pobail.ie
On 1 June 2006 the Criminal Law (Insanity) Act 
2006 came into effect. The Act contains clear 
statutory rules in relation the defence of insanity 
and the related question of a person’s fitness to be 
tried. For the purposes of the Act, ‘mental disorder’ 
is defined as a mental illness or handicap, dementia 
or any disease of the mind. Intoxication by alcohol 
or other substances is explicitly excluded from the 
scope of the definition. www.justice.ie 
On 2 June 2006 Democracy, Cities and Drugs 
held its second conference, in Ghent, Belgium, on 
local and participative responses to the issue of drug 
use. Topics included how to develop municipal 
drug strategies and action plans; how to create and 
maintain a multi-agency partnership; how to increase 
the involvement of communities in local drug 
policies; and how to change conflicts into consensus. 
www.democitydrug.org 
On 6 June 2006 the Health Service Executive 
(HSE) released its first annual report. It contains 
an account of an Alcohol Detox Unit for people 
who are homeless, established by the Primary, 
Community and Continuing Care (PCCC) 
Directorate in partnership with the Dublin Simon 
Community. In 2005, 156 people were admitted 
to the programme, of whom 80% completed the 
7–10 day detox programme, and 66% completed 
the 21-day detox programme. Staff working on the 
programme have been trained in the Community 
Reinforcement Approach (CRA) to addiction 
treatment. www.hse.ie 
On 26 June 2006 the United National Office on 
Drugs and Crime (UNODC) selected ‘Drugs are not 
child’s play’ as the theme of its 2006 international 
campaign against drug abuse and illicit trafficking. 
The objective is to increase public awareness 
about the destructive power of drugs and society’s 
responsibility to care for the well-being of children 
aged 4 to 10. For further information on the 
campaign, see www.unodc.org/unodc/event_2006-
06-26_1.html 
On 6 July 2006 the Parole Board released its 2005 
annual report. In relation to drug use in prisons, 
the Board comments: ‘The Board views with great 
dismay the fact that drugs are available in so many 
places of detention in the country. We have even 
seen examples of prisoners who went on drugs for 
the first time whilst in custody. Whilst this difficulty 
arises in other jurisdictions the information we have 
gathered reveals that it is far less prevalent than 
in Irish prisons and what can be done in other 
jurisdictions can surely be done here. The intention 
of the Minister and the prison service to cut out 
the availability of drugs in prisons must be fully 
supported.’ www.justice.ie 
On 6 July 2006 the National Educational Welfare 
Board (NEWB) released its analysis of school 
attendance for the school year 2004/2005. It shows 
that attendance has improved in many of the areas 
targeted specifically by NEWB, such as primary and 
post-primary schools in designated disadvantaged 
areas. In a number of these targeted areas, the mean 
percentage of students absent on 20 days or more 
has declined by over 4%, compared to 2003/2004. 
www.newb.ie 
On 10–11 July 2006 the Council of Europe 
Pompidou Group held a seminar on ‘Road Traffic 
and Drugs’. The seminar heard that,while alcohol is 
recognised as a major road safety problem, alcohol 
combined with cannabis considerably increases the 
risk of fatal accidents. Also highlighted were the lack 
of reliable tests to detect cannabis use, and the major 
differences between European countries’ legislation 
and penalties in respect of drink and drug driving. 
www.coe.int/t/dg3/pompidou/ 
In July 2006 the World Customs Organization 
(WCO) released its definitive 2005 report on 
Customs and Drugs, an annual report that provides 
a global overview of drug trafficking. It reports 
trends and statistics for individual drugs, including 
heroin, cocaine, cannabis resin, herbal cannabis, 
amphetamines, MDMA (Ecstasy), methamphetamine 
and khat (Catha edulis). www.wcoomd.org 
On 2 August 2006 the Guidelines for Developing 
a School Substance Use Policy, published in 2002 
by the Department of Education and Science, 
were augmented by the publication of support 
materials, including a template prompt document 
outlining issues to consider and questions to ask 
when developing a substance use policy, and a 
sample alcohol, tobacco and drug use policy. The 
materials are intended to assist school authorities in 
developing their own policies. www.education.ie
On 31 August 2006 The Irish Times reported that the 
Government had deferred publication of its annual 
progress report on the Agreed Programme for 
Government, usually published in July. It is instead 
considering a more comprehensive pre-election 
account of its time in power. The Agreed Programme 
contains five new initiatives not contained in the 
National Drugs Strategy, which are intended to 
contribute to achieving drug-free prisons, reducing 
drug supply and improving information regarding 
the drug situation.  
www.ireland.com 
(Compiled by Brigid Pike)
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In brief (continued)
Responses: Cigarettes, alcohol and colonisation
Cited from Peter Thomas, Drugnet Europe, No. 55, 
July–September 2006
‘I have learned not to try to convince people 
about what to do. I consider the task of trying 
to convince others a lack of personal respect, an 
attempt at colonisation’, wrote José Saramago. The 
reticence of the Portuguese Nobel prize-winning 
author provided the perfect challenge to health 
professionals active in the field of licit and illicit 
drugs attending the first EMCDDA expert meeting 
on ‘environmental prevention strategies’ held in 
Lisbon from 29–30 June.
This was the first EMCDDA event to focus on 
legal psychoactive substances, in the context of 
the agency’s current task to examine polydrug 
use. Presentations were delivered on tobacco 
and alcohol regulation, and on the evidence base 
for environmental approaches to psychoactive 
substance use prevention. Case studies described 
environmental approaches to reducing smoking 
and drinking in Ireland, Malta, Poland and the UK.
Professionals working in the fields of both licit and 
illicit psychoactive substances – disciplines often 
kept apart – were able to debate topics such as the 
potential cross-substance effects of smoking bans, 
aggressive marketing which encourages binge 
drinking; and the poor impact of school education 
and health promotion campaigns, particularly 
those demonising drugs. Based on discussions 
at the event, evidence suggests that ‘macro-
environmental’ measures can offer better value 
prevention than those focused on persuading the 
individual. However, regulatory measures can face 
obstacles, such as the political resistance to universal 
measures and defensive lobbying by vendors. 
While colonisation of the mind is rarely the agenda, 
what is certain is that regulation has a valuable 
role to play in changing cultural attitudes towards 
psychoactive substances, whether the laudanum or 
absinthe of the past, or today’s alcopops, cigarettes 
and vertical drinking. A full follow-up report of the 
event will be published in the autumn.
Drugs-Lex – Europe’s diverse drug-driving laws 
presented at Pompidou Group seminar
Cited from Brendan Hughes, Drugnet Europe, No. 
55, July–September 2006
The latest ELDD ‘Topic overview’ (http://eldd.
emcdda.europa.eu), describing the laws and 
penalties regarding drugs and driving across 
the EU, was presented at the Pompidou Group’s 
‘Third seminar on road traffic and drugs’ held in 
Strasbourg from 10–11 July. …The ‘Topic overview’ 
updates and expands on groundwork carried 
out in 2003 (see ELDD ‘Legal reports’). The new 
document examines: the status of the offence 
(criminal/non-criminal); the substances forbidden 
by law; whether police may stop to test at random 
or only on suspicion; and whether there is zero 
tolerance (any trace of drugs) or whether a certain 
level of impairment is required before prosecution. 
The paper also looks at the various sanctions 
available by country, particularly the range of 
fines and prison sentences and the possible period 
for suspension of a driving licence. The overview 
shows that, although all Member States list ‘drug 
driving’ as an offence, the conditions for its 
prosecution and the range of possible penalties can 
vary massively between countries.
Drugnet Europe is the quarterly newsletter 
of the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA). 
An electronic version of Drugnet Europe is 
available on the EMCDDA website at www.
emcdda.europa.eu
If you would like to receive a hard copy 
of the current or future issues of Drugnet 
Europe, please contact: Drug Misuse 
Research Division, Health Research Board, 
Knockmaun House, 42–47 Lower Mount 
Street, Dublin 2. Tel: 01 676 1176 ext 127; 
Email: dmrd@hrb.ie
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From Drugnet Europe
Recent publications
Books
Theory of addiction
West R, with Hardy A
Blackwell Publishing 2006, 211 pp. 
ISBN-13  978 1 4051 1 1359 6
In the preface to this book, the author explains the 
theory of addiction as ‘a theory of motivation and 
how the motivational system is distorted in the 
case of addiction’.  An understanding of addiction 
theory is vital to the understanding addiction itself. 
This book aims to develop this understanding 
by taking a journey to the development of a 
synthetic theory of 
addiction, beginning 
with the simplest possible 
common-sense approach 
and exploring how 
the theory needs to be 
extended or changed 
to take account of the 
available evidence. 
The goal is to end up 
with a theory that is 
‘parsimonious, coherent, 
original, stimulating 
and above all useful’. 
West’s scheme for 
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communicating the theory has five key themes: the 
structure of the motivational system; the moment-
to-moment control of behaviour; the plasticity of 
the motivational system; identity; and the unstable 
mind.  
The first six chapters cover the existing theories 
by working through the various approaches 
to understanding addiction. Chapter 7 takes 
the reader through the development of a 
comprehensive theory, starting with the simplest 
rational-choice model and extending it to a 
model that involves concepts of self-control and 
impulse, and then habit. Chapter 8 sets out the 
first draft of a synthetic theory of motivation 
and introduces the acronym ‘p.r.i.m.e.’ (plans, 
responses, impulses, motives and evaluations) 
to refer to the five levels of complexity at which 
the human motivational system works. The final 
chapter returns to the concept of addiction and 
examines how the p.r.i.m.e. theory of motivation 
helps in understanding the various manifestations 
of addiction. 
Designed to enable students, practitioners and 
researchers to find a starting point in the complex 
world of addiction theory, Theory of Addiction 
recognises the diversity of the experience of 
addiction, discusses factors at the level of both 
the individual and populations and provides key 
recommendations for the development of effective 
interventions.
ABC of alcohol  
(4th edition)
Paton A and  
Touquet R (eds)
Blackwell Publishing 
2005, 57 pp.
ISBN-13 978 0  
7279 1814 7
The objective of the 
first edition of ABC 
of alcohol in 1988 
was to encourage 
doctors to regard alcohol misuse as a legitimate 
part of professional practice. The editors of this 
latest edition believe that this aim has not been 
realised fully in the intervening years, that in some 
quarters the feeling is still that doctors should not 
get involved.  They suggest that this is largely 
because of lack of knowledge about how misuse 
of alcohol affects society and people, and thus a 
lack of confidence in tackling misuse. This book 
is designed to remedy this and to show that 
sympathetic management of people with alcohol 
problems, especially if they are detected early, can 
be a rewarding experience. 
In this edition, existing chapters have been revised 
and important sections have been added on the 
impact of alcohol on accident and emergency 
departments and surgical practice, and on the 
potential dangers of alcohol’s interaction with 
legal and illegal drugs. The editors have tried to 
broaden the ‘doctor–patient’ model to encompass 
alcohol workers and their clients. Designed, as a 
practical reference guide, this book has chapters 
on the wider social consequences of alcohol 
misuse; the physiological and pathological effects 
of alcohol on the body; definitions of healthy and 
of harmful drinking; the nature of alcohol use; 
detecting misuse; medical and surgical problems; 
management of alcohol misuse in primary care; 
advice and counselling; treatments; and resources.    
Clinical textbook of 
addictive disorders 
(3rd edition)
Frances RJ, Miller SI  
and Mack AH (eds)
The Guilford Press 2005, 
684 pp.
ISBN 1 59385 174 X 
(hardcover)
The revised and 
expanded third edition 
of this book presents 
the latest scientific knowledge about all aspects of 
addictive disorders and their treatment. Leading 
researchers and practitioners describe best practices 
in assessment and diagnosis and provide the latest 
tools for working with users of specific substances. 
Divided into five parts, the book begins by 
describing the scientific foundations and historical 
background of addictions treatment. Current 
procedures for psychological evaluation and 
laboratory testing are then outlined. Subsequent 
sections provide substance-specific information 
and examine issues in working with particular 
populations, including polysubstance users, 
culturally diverse patients, women and older 
adults. Next, widely used psychological and 
pharmacological treatment approaches are 
thoroughly reviewed. Attention is given throughout 
to the importance of tailoring interventions to each 
patient’s needs while delivering compassionate, 
evidence-based care. With expanded coverage 
of co-morbidity and dual diagnosis, the third 
edition contains entirely new chapters on the 
neuroscientific basis of addiction, addiction to 
gambling and to pain medications and substance 
abuse in the workplace, as well as a chapter on 
dialectical behaviour therapy.  
This clinical textbook will be of interest to 
practitioners, graduate students and others 
in a range of disciplines, including psychiatry, 
clinical psychology, social work, substance abuse 
counselling and allied health fields. It is used as a 
core text for courses in addiction psychiatry and 
substance abuse counselling.
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Evidence-based policy: 
a realist perspective
Pawson R
Sage Publications 2006, 
196 pp.
ISBN-13  978 1 4129 
1060 6 (paperback)
The author tells us that 
choosing a title for this 
book was troublesome.  
The problem with the 
term ‘evidence-based 
policy’, he says, is that there is no such thing. He 
tells the reader that what they are about to read 
is – (The best we can do by way of) evidence-
based policy: a realist (in one sense of the term) 
perspective.
Chapter 1 identifies the main vehicle for evidence-
based policy. Current hopes are pinned on rigorous 
‘systematic reviews’, which attempt to synthesize 
the entirety of evidence on existing interventions. 
Chapter 2 introduces realist methodology, both 
as a philosophy of social inquiry and as a tool for 
dissecting the workings of social interventions. 
Chapter 3 is a critical interlude examining ‘meta-
analysis’, currently the dominant model for 
research synthesis. Chapter 4 is the pivot of the 
book, introducing a new model of systematic 
review and setting down at length the principles 
and practice of ‘realist synthesis’. 
Chapter 5 is the first of three providing illustrations 
of realist synthesis. The evidence on the USA’s sex 
offender registration and community notification 
programme (Megan’s Law) is reviewed in order to 
show how and how much the success of complex 
interventions depends on the efficacy of each step 
in a long implementation chain. Chapter 6 offers a 
review of youth mentoring programmes, to show 
how realist synthesis can fine-tune understanding 
of the inner workings of programmes. Chapter 
7 is a realist synthesis of ‘naming and shaming’ 
interventions. The aim is to compare the same 
initiative in action in very different policy spheres 
in order to demonstrate the contextual sensitivity 
of a key weapon of public policy. Chapter 8 asks 
the question: Does this dose of realism about the 
nature of the evidence base change expectations 
about its capacity to infiltrate the policy process?
Journal articles
 
The following abstracts are from a selection of 
articles relating to the drugs situation in Ireland 
recently published in international journals.
Booting and flushing: needle rituals and risk for 
bloodborne viruses 
McElrath K
Journal of Substance Use 2005; 11(3): 177–189  
‘Booting’ and ‘flushing’ are terms used to describe 
an injecting behaviour in which the plunger is 
pulled back and the fluid (mostly blood and 
perhaps blood only) is re–injected. The behaviour 
differs from ‘registering’, which occurs before the 
drug is injected. Booting/flushing can produce 
subcutaneous and venous damage, and increases 
the risk of the spread of blood-borne viruses when 
used equipment is passed on to other injectors. 
The purpose of the study was to explore the 
extent of flushing, the context of flushing and 
IDUs’ self-reported reasons for flushing. Data were 
collected through semi-structured interviews with 
59 IDUs in Northern Ireland, recruited by various 
strategies. Respondents’ ages ranged from 22 to 50 
years and females comprised 34% of the sample. 
Mean length of injecting career was 8.3 years. A 
total of 46% reported flushing on a regular basis 
during some or most of their injecting career. The 
results showed that flushing occurs for different 
reasons and is not associated solely with cocaine 
or speedball injection. Interventions designed 
to reduce the extent of flushing must take into 
account the various reasons for the behaviour.
 
Review of a community-based youth counselling 
service in Ireland 
Lalor K, O’Dwyer S and McCrann D 
Children and Youth Services Review 2005; 28(3): 
325–345
The structure and operation of a community-based 
youth counselling service operated by the Kildare 
Youth Services (KYS), Ireland, are examined with 
a view to highlighting the preventative nature of 
such a service. Presenting problems are explored in 
the context of the wider social milieu. Particularly, 
recent trends in sexual behaviour, substance abuse 
and child sexual abuse are examined. Interviews 
were conducted with a sample of professionals 
who referred clients, patients and students to the 
KYS Youth Counselling Service. Interviews were 
also conducted with a small sample of clients of 
the service and with the counsellor-co-ordinator 
of the service. The service was viewed positively 
throughout the community and its role in the 
prevention of further distress was highlighted. 
Economic and cultural correlates of cannabis use 
among mid-adolescents in 31 countries  
ter Bogt T, Schmid H, Nic Gabhainn S, Fotiou A 
and Vollebergh W
Addiction 2006; 101(2): 241–251
The aim of this study was to examine cannabis 
use among mid-adolescents in 31 countries and 
associations with per-capita personal consumer 
expenditure (PCE), unemployment, peer factors 
and national rates of cannabis use in 1999.  The 
authors used results from the Health Behaviour in 
School-aged Children (HBSC) study, a collaborative 
cross-national research study supported by WHO/
Europe. The sample was nationally representative 
and consisted of a self-report survey of 22,223 
male and 24,900 female 15-year-olds. Country 
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characteristics were derived from publicly available 
economic databases and previously conducted 
cross-national surveys on substance use.
Anglo-American countries (Canada, UK, US) and 
Switzerland and Greenland have a relatively high 
prevalence of lifetime cannabis use, whereas most 
countries from eastern and northern Europe, 
except Czech Republic, Hungary, Slovenia and 
Ukraine, have a low prevalence. Mediterranean 
countries, except Spain and to a lesser extent 
Italy and Portugal (Malta, Israel, Greece and 
Macedonia) also tend to have relatively low 
prevalence estimates. Most western European 
countries rank in mid-range (Belgium, Denmark, 
France, Germany, Ireland, the Netherlands). On 
the whole, boys have higher prevalence rates than 
girls, gender differences generally being greatest in 
eastern and southern European countries. Overall, 
lifetime prevalence and frequent use are associated 
with PCE, perceived availability of cannabis (peer 
culture) and the presence of communities of older 
cannabis users (drug climate).
The authors conclude that, as PCE increases, 
cannabis use may be expected to increase and 
gender differences decrease. Cross-national 
comparable policy measures should be developed 
and evaluated to examine which harm reduction 
strategies are most effective.
’Harry Wynne‘ Child and youth care practices 
and values: a reflection on a study of heroin 
misusers in Ireland 
McElwee, NC  
Child & Youth Care Forum 2006; 35(2):205–217
This discussion paper sets out to explore ‘doing’ 
research with a hard-to-reach population from a 
relational child and youth care perspective. It sets 
out some of the delimitations in undertaking such 
research and discusses some of our findings in 
relation to the individual and the family contexts.
Drug treatment programmes in prison: 
longitudinal outcome evaluation, policy 
development and planning interventions 
Pugh J and Comiskey CM  
Irish Journal of Psychological Medicine 2006 23(2): 
63–67
The aim of this research is to evaluate a seven-week 
abstinence-based drug treatment programme and 
to use this to assist policy makers in the planning 
and provision of future programmes. Seventy-
nine clients were interviewed at two stages: stage 
I, prior to the treatment programme: stage II, 
immediately after the treatment programme. A 
selected group of 20 clients were followed up and 
interviewed at stage III, up to 24 months after 
the treatment programme. This latter sample 
of 20 clients consisted of eight prisoners who 
had re-offended and returned to prison, three 
prisoners who were still in prison serving their 
original sentence and nine prisoners who were 
out of prison. These 20 also participated in a more 
detailed quantitative and qualitative survey. All 
clients were prisoners at Mountjoy Prison, Dublin 
Ireland.
In order to measure the prisoners’ criminogenic 
attitudes and needs, the Crime Pics II instrument 
was used. This is a semantic differential scale which 
measures attitudes toward offending behaviour. It 
includes a problem checklist which can be used to 
measure change over time.
An 82% follow-up rate was achieved on the 
original group of 79 clients, and a follow-up rate 
of 100% for the selected group of 20 clients 
who were interviewed three times. Regardless 
of category of client, findings demonstrate an 
improvement over time for the outcome variables, 
general attitude to offending, anticipation of re-
offending and perception of current life problems. 
However, the study failed to demonstrate any 
significant change for the outcome variables, victim 
hurt, denial and evaluation of crime.
These results were short-lived for many prisoners, 
who failed to sustain the gains made. Interviews 
with the cohort of 20 suggest that clients who 
did not receive continuity of treatment post 
programme, in terms of case management and 
structured treatment, did not fare as well as those 
who received such treatment.
Psychiatric morbidity in the male sentenced Irish 
prisons population
Duffy D, Linehan S and Kennedy HG 
Irish Journal of Psychological Medicine 2006; 23(2): 
54–62
 
This is the first epidemiologically representative 
cross-sectional study of psychiatric morbidity using 
research diagnostic instruments in sentenced 
prisoners in Ireland. The aim of the research 
was to estimate the prevalence of psychiatric 
morbidity and psychiatric service requirements. 
The authors interviewed 340 men serving a fixed 
sentence (14.6% of total) and 98 men serving a 
life sentence (82% of total). Prisoners were drawn 
from 15 different prisons using a random stratified 
sampling method. Mental illness and substance 
misuse were measured using the SADS-L, SODQ 
and a structured interview to generate ICD-10-DCR 
diagnoses. A high prevalence of mental illness was 
found. The six-month prevalence for psychosis 
(2.7%) was similar to an international meta-
analysis. The authors found a significantly higher 
prevalence of psychosis in life-sentence prisoners 
(6.1%) than in fixed-sentence prisoners (1.8%). 
Drugs and alcohol problems were very prevalent.
Using the six-month prevalence figures found 
for psychosis, the authors estimate that there are 
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approximately 79 sentenced male prisoners with a 
severe mental illness who would require treatment 
in hospital additional to current provision. The 
relationship between drug availability and the 
prevalence of severe mental illnesses in prisons is 
also discussed.
 
Psychiatric morbidity among women prisoners 
newly committed
Wright B, Duffy D, Curtin K, Linehan S, Monks S 
and Kennedy HG
Irish Journal of Psychological Medicine 2006;  
23(2): 47–53
The aim of the research was to estimate the 
prevalence of psychiatric morbidity, substance 
misuse problems and related health and social 
problems among women prisoners newly 
committed and a cross-section remanded and 
sentenced. In 2002 women represented 10.7% 
(1043) of all persons committed to the Irish prison 
system, and 3.3% (104) of the daily average 
number of persons in custody. The authors 
surveyed psychiatric morbidity in these two groups 
to assess the need for psychiatric services for 
women prisoners, and to compare Irish morbidity 
with an international average. 
Ninety-four newly committed women 
prisoners were interviewed within 72 hours of 
committal, representing approximately 9% of 
female committals per year. The authors also 
interviewed a cross sectional sample of 92 women, 
representing approximately 90% of all women 
in custody. Mental illness and substance misuse 
were measured using the SADS-L, SODQ and a 
structured interview. Five (5.4%) of the committal 
and 5 (5.4%) of the cross-sectional sample had a 
psychotic illness within the previous six months; 
8 (8.5%) of the committal and 15 (16.3%) of the 
cross-sectional sample had a major depressive 
disorder in the last six months. Eight (8.6%) of the 
committal and 14 (15.2%) of the cross-sectional 
sample had an anxiety disorder within the last 
six months. Sixty-one (65.6%) of the women 
interviewed at committal and 61 (65.2%) of the 
cross-sectional sample had a substance misuse 
problem in the last six months.
There is a high prevalence of mental illness and 
substance misuse problems among women newly 
committed to prison and in a cross section of those 
remanded or sentenced in Ireland. The authors 
found evidence of a cycle of deprivation and 
institutionalisation. These findings highlight the 
need for the integration of community and forensic 
psychiatric services, and for ongoing collaboration 
with drug services.
 
 
The social contexts of drinking among Irish men 
in London
Tilki M 
Drugs: Education, Prevention & Policy 2006;  
13 (3): 247–261
This article reports the alcohol-related findings of a 
qualitative study that examined health beliefs and 
behaviours among Irish people in London. The 
findings elicited though key informant and lay focus 
groups and semi-structured interviews, illuminated 
the social and socioeconomic background to 
excessive alcohol use among middle-aged Irish men 
who left Ireland in the 1960s and 1970s. The findings 
describe the economic role of the pub and alcohol for 
men in the construction industry as well protecting 
them from homesickness, isolation and alienation 
in an unwelcoming and hostile environment. They 
illustrate the use of alcohol later in life to cope with 
physical and psychological pain, social stress and the 
symptoms of mental illness. The use of alcohol as a 
culturally sanctioned coping strategy is considered, 
exploring the ambivalent culture of alcohol in 
Ireland and in particular the tolerance of excessive 
consumption among men. The article explores 
the possibility that tolerant attitudes to alcohol in 
Ireland persist on migration to Britain and are then 
confounded by a culture of binge drinking among 
young people in general. The conclusion argues for 
further research and for culturally sensitive healthcare 
and health promotion strategies that take account of 
cultural and structural factors impacting on young 
Irish men in Britain. Current NHS policies on equality, 
alcohol and suicide offer timely opportunities to 
address alcohol misuse in order to improve physical 
and mental health and reduce the incidence of 
suicide among Irish men in Britain.
(Compiled by Louise Farragher and Joan Moore)
September 2006
18 September 2006
The Drug Treatment Centre Board 
2006 Autumn Educational Seminars
Venue: Newgrange Hotel, Navan, Co 
Meath
Organised by / Contact: Drug Treatment 
Centre Board
Tel: + 353 (01) 6488600
www.addictionireland.ie/events
Information: The Drug Treatment Centre 
Board will present a series of seminars 
in Meath, Donegal and Kilkenny. With 
a range of speakers including Dr Brion 
Sweeney, Dr Bobby Smyth, Dr Joe Barry, 
Dr Declan Bedford and Dr Des Corrigan, 
the programme will address issues such 
as the 4-Tier Model, Development of 
Adolescent Services, Drugs and Alcohol 
and the Effects of Psychoactive Drugs. 
21 September 2006
27th Annual EAP Conference & 
Training Institute. Managing the 
Performance, Safety & Health Risks of 
Employee Drug & Alcohol Use
Venue: Stillorgan Park Hotel, Dublin
Organised by / Contact: Miriam Tobin, 
Conference Administrator, 
EAP Institute, 143 Barrack Street, 
Waterford, Ireland
Tel: +353 (0)51 855799
Fax: +353 (0)51 879626
Email: eapinstitute@eircom.net
21–23 September 2006
ESSD: European Society for Social Drug 
Research – 17th Annual Conference 
Venue: Lisbon, Portugal
Organised by / Contact: Maria do 
Carmo Gomes, Researcher/Sociologist,
Centre for Research and Studies in 
Sociology (CIESISCTE)
carmo.gomes@iscte.pt
Tel: +351 21 790 3077
Information: ESSD was founded in 1990 
as an association of European social 
scientists working on drug issues. Its 
principal aim is to promote social science 
approaches to drug research, with special 
reference to the situation in Europe. The 
society holds annual conferences and 
workshops, co-ordinates research and 
organises joint projects.
October 2006
4 October 2006
The Drug Treatment Centre Board 2006 
Autumn Educational Seminars
Venue: Mill Park Hotel, Donegal Town, Co 
Donegal
Organised by / Contact: Drug Treatment 
Centre Board
Tel: + 353 (01) 6488600
www.addictionireland.ie/events
5–7 October 2006
9th European Conference on Drugs and 
Infections Prevention in Prison. From the 
Principle of Equivalence to the Practice 
of Care: Bridging the Gap.
Venue: Grand Hotel Union, Ljubljana, 
Slovenia
Organised by / Contact: Cinzia Brentari, 
Rue Hotel des Monnaies 52, 1060 Brussels, 
Belgium. 
Tel: +32 (0)2 5380171
cbrentari@cranstoun.org.uk 
Information: This year’s conference 
is structured to provide opportunities 
for dialogue on the development 
and implementation of effective drug 
prevention and health promotion policies 
and services for those who come into 
contact with the criminal justice system.
6–8 October 2006   
EUROPAD 7 European 
Venue: Radisson SAS Hotel, Bratislava
Organised by / Contact: European Opiate 
Addiction Treatment Association & Slovak 
Professional Society for Dependencies on 
Psychoactive Substances. 
Email: maremman@med.unipi.it 
www.europad.org/conf2006.asp 
9–11 October 2006 
9th International Symposium on 
Substance Abuse Treatment
Venue: National Research and 
Development Centre for Welfare and 
Health (STAKES) in Helsinki, Finland.
Organised by / Contact: Mari Miekkala, 
Research Assistant
Tel: +358 (0)9 3967 2004
Email: mari.miekkala@stakes.fi 
www.nad.fi/sat2006/ 
Information: This symposium will cover 
the following topics:
•   Characteristics and assessments of 
treatment systems: what clients are 
reached by different treatment systems 
and what treatment is offered to 
different clients?
•   Brief interventions and internet-based 
services – theory and practice: Do 
these practices reach new client groups 
and how do they work, for instance, in 
case of drug problems?
•   Treatment in prison settings – contexts 
and qualities
•   Therapeutic communities 
– characteristics and their role in 
different treatment systems
•   Harm reduction and treatment 
– new division of labour or changed 
ambitions?
12 October 2006
Alcohol and Drug Problems in 
Contemporary Ireland
Venue: Swift Lecture Theatre, Arts 
Building, Trinity College Dublin, Thursday 
evenings, 7.30pm – 9.00pm
Contact / Organised by: Application 
forms are available from The Executive 
Officer, Addiction Studies, School of 
Social Work and Social Policy, Arts 
Building, Trinity College, Dublin 2
Tel: +353 (0)1 608 1163 (mornings)
Email: addiction.studies@tcd.ie
Fee: €100 payable in advance (reduced 
fee for unemployed people and 
pensioners). Cheques to be made payable 
to TCD No. 1 Account.
Information: This evening course, a 
series of 10 lectures, will be given by 
lecturers and practitioners who contribute 
to the Diploma in Addiction Studies and 
the MSc in Drug & Alcohol Policy which 
are run in the School of Social Work.  
The first lecture takes place on 12 
October 2006. The lecture topics and 
speakers are: 
•   Alcohol and Drug Use: Complex 
Problems & Simplistic Solutions 
(Marguerite Woods)
•   Alcohol Policy in Ireland (Shane Butler)
•   Drug Policy: the International 
Dimension (Eoghan Quigley)
•   Alcohol and Drug Education as a 
Means of Prevention (Marguerite 
Woods)
•   Alcohol and the Family (Shane Butler)
•   The Role of 12-Step Fellowships (Tony 
Jordan)
•   Harm Reduction in a Drug-free Culture 
(Shane Butler)
•   Women and Drug Use (Marguerite 
Woods)
•   Youth and Drugs (Mary Cunningham)
•   Drug Problems: the Community 
Dimension (Barry Cullen)
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17 October 2006
The Drug Treatment Centre Board 2006 
Autumn Educational Seminars
Venue: Kilkenny River Court, Kilkenny
Organised by / Contact: Drug Treatment 
Centre Board
Tel: + 353 (01) 6488600
www.addictionireland.ie/events
November 2006
8 November 2006
Drug & Alcohol Professionals Conference
Venue: Royal Institute of British Architects, 
66 Portland Place, London
Organised by / Contact: The Federation 
of Drug & Alcohol Professionals (FDAP) in 
association with Drink & Drugs News
www.fdap.org.uk  
Information: FDAP’s Annual Drug & Alcohol 
Professionals Conference aims to support the 
development of front-line workers, managers 
and commissioners, and to give delegates 
the opportunity to have their say on 
important issues of the day. This year’s event 
will include plenary presentations on the 
future of alcohol services, residential rehab 
and harm reduction, as well as the next 
steps on workforce development. Workshops 
and seminars will cover issues such as: 
services for steroid users; meeting the needs 
of young people; working with clients 
with co-occurring gambling problems; 
brief therapies for alcohol problems; and 
managing child protection issues. Delegates 
will have the chance to contribute to policy 
debates on: whether psychological therapies 
work with substance users; what role, if any, 
there should be for coercive treatment; and 
whether practitioners should have to be 
qualified to work in this field.
15 November 2006
2nd National Conference on Reducing 
Drug-Related Deaths
Venue: The Lowry Hotel, Manchester
Organised by / Contact: Salman Desai, 
Greater Manchester Ambulance Service NHS 
Trust, Ladyridge Hall, 399 Chorley New 
Road, Bolton BL1 5DD. Tel: +44 (0)1204 
492419
Email: info@gmas.nhs.uk 
Information: Reducing drug-related deaths 
(DRDs) remains a key issue for all services. 
This one-day conference will explore the 
causes, impacts and ways to reduce DRDs. 
Themes include the provision of Naloxone 
for users, blood-borne viruses, abstinence 
vs maintenance, and the role of prisons in 
reducing DRDs.
The conference will be of interest to DATs; 
drug, mental health and ambulance services, 
police, prisons, probation, professionals 
working in primary and social care, accident 
and emergency staff, coroners, directors of 
public health, researchers and service users.
 
16–17 November 2006
International child psychiatry conference 
on the treatment of adolescent addiction
Venue: The Davenport Hotel, Merrion 
Square, Dublin 2
Fee:  €295.00 per delegate 
Organised by / Contact: Drug Treatment 
Centre Board (DTCB). To request a 
brochure, reserve a place or for queries 
please call +353 (0)1 648 8750 
Email: seminars@dtcb.ie 
www.dtcb.ie             
Information: International best practice 
indicates that treatment of severe adolescent 
addiction problems should involve dedicated 
input by a multi-disciplinary team. The 
Young Persons Programme at the DTCB 
deals with the most complex cases of 
adolescent addiction and has substantial 
experience and real expertise within this 
field. There is growing awareness of the 
need for child and adolescent psychiatrists 
to become more involved in the provision 
of addiction treatment to teenagers with 
substance misuse difficulties. 
The main learning objective of the DTCB’s 
two-day conference is to equip attendees 
with the basic skills to conduct assessments 
of complex adolescent addiction cases and 
to develop treatment plans to tackle the 
problems identified. The format will involve 
a combination of lectures, case discussions, 
small-group work and workshops dealing 
with very specific area of treatment.  Key 
team members from the DTCB Young 
Persons Programme, including Dr Gerry 
McCarney and Dr Bobby Smyth, will deliver 
this conference with special guest speaker Dr 
KAH Mirza.
 
January – March 2007
Managing the Performance, Safety 
and Health Risks of employee drug and 
alcohol use
Organised by / Contact: Anita Furlong, 
EAP Institute 143 Barrack Street, Waterford, 
Ireland
Tel: +353(51)855733
Fax: + 353(51)879626
Email: maurice@eapinstitute.com
www.eapinstitue.com 
Thursday 18 January 2007
Venue: Ramada Viking Hotel, Waterford
Thursday 15 February 2007
Venue: Heritage Hotel, Portlaoise
Thursday 8 March 2007
Venue: Radisson Hotel, Galway
Information: The Safety, Health and Welfare 
at Work Act 2005 was signed into law in 
June 2005. The Act requires employees not 
to be under the influence of intoxicants 
(defined as drugs and alcohol) to the extent 
that they endanger their own or another 
person’s safety at work.  The purpose of 
this seminar is to outline the impact of 
drug impairment in the workforce and give 
practical guidance on the recognition and 
treatment of employees whose behaviour 
presents risks to themselves and others. 
The Drug Misuse Research Division 
(DMRD) of the Health Research 
Board is a multi-disciplinary team of 
researchers and information specialists 
who provide objective, reliable and 
comparable information on the 
drug situation, its consequences and 
responses in Ireland. The DMRD 
maintains two national drug-related 
surveillance systems and is the 
national focal point for the European 
Monitoring Centre for Drugs and Drug 
Addiction. The division also manages 
the National Documentation Centre 
on Drug Use. The DMRD disseminates 
research findings, information and 
news through its quarterly newsletter, 
Drugnet Ireland, and other publications. 
Through its activities, the DMRD 
aims to inform policy and practice in 
relation to drug use.
 
Drugnet Ireland mailing list
If you wish to have your name 
included on the mailing list for future 
issues of Drugnet Ireland, please send 
your contact details to:
Drug Misuse Research Division, 
Health Research Board, Knockmaun 
House, 42–47 Lower Mount Street, 
Dublin 2. Tel: 01 676 1176 ext 127; 
Email: dmrd@hrb.ie
Please indicate whether you would 
also like to be included on the 
mailing list for Drugnet Europe and 
Drugs in focus.
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